Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof

ABSTRACT

Disclosure provides a formulation of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin and to augment the biological activity of curcumin, wherein curcumin is the main constituent of curcuminoid and wherein Ar-turmerone is the main constituent of the essential oil of turmeric. An application of curcuminoid with essential oil of turmeric to enhance the bioavailability of curcumin for oral supplementation against a variety of diseases and method of doing the same is provided.

This application is a divisional of co-pending U.S. application Ser. No.13/645,031 filed Oct. 4, 2012, which is a continuation-in-part of PCTApplication Serial No. PCT/IN2011/000232, filed Apr. 4, 2011, whichclaims priority of Indian Provisional Application Serial No.950/CHE/2010, filed Apr. 5, 2010, and a continuation-in-part ofco-pending U.S. application Ser. No. 14/094,725, filed Dec. 2, 2013,which is a divisional of U.S. application Ser. No. 13/385,717, filedMar. 5, 2012, which is a divisional of Ser. No. 12/926,985 filed Dec.21, 2010, which is a divisional of Ser. No. 12/662,740 filed Apr. 30,2010, which is a divisional of U.S. application Ser. No. 11/635,599filed Dec. 8, 2006, which is a continuation of PCT Application SerialNo. PCT/IN05/00176, filed May 30, 2005, and a continuation-in-part ofco-pending U.S. application Ser. No. 13/674,249, filed Nov. 12, 2012,which is a divisional of Ser. No. 13/506,572, filed Apr. 30, 2012, whichis a divisional of Ser. No. 12/926,980, filed Dec. 21, 2010, which is adivisional of Ser. No. 12/073,864, filed Mar. 11, 2008, which is acontinuation-in-part of Ser. No. 11/635,599, filed Dec. 8, 2006, whichis a continuation of PCT Application Serial No. PCT/IN05/00176, filedMay 30, 2005, all of which applications are incorporated in entirety byreference. U.S. application Ser. No. 13/645,031 filed Oct. 4, 2012, is acontinuation-in-part of U.S. application Ser. No. 13/385,717, filed Mar.5, 2012, which is a divisional of Ser. No. 12/926,985 filed Dec. 21,2010, which is a divisional of Ser. No. 12/662,740 filed Apr. 30, 2010,which is a divisional of U.S. application Ser. No. 11/635,599 filed Dec.8, 2006, which is a continuation of PCT Application Serial No.PCT/IN05/00176, filed May 30, 2005; and, a continuation-in-part of Ser.No. 13/506,572, filed Apr. 30, 2012, which is a divisional of Ser. No.12/926,980, filed Dec. 21, 2010, which is a divisional of Ser. No.12/073,864, filed Mar. 11, 2008, which is a continuation-in-part of Ser.No. 11/635,599, filed Dec. 8, 2006, which is a continuation of PCTApplication Serial No. PCT/IN05/00176, filed May 30, 2005, all of whichapplications are incorporated in entirety by reference.

OBJECTIVE OF THE INVENTION

The following specification describes an invention which relates to aformulation of curcuminoid with essential oil of turmeric to enhance thebioavailability of curcumin and to augment the biological activity ofcurcumin, wherein curcumin is the main constituent of curcuminoid andwherein Ar-turmerone is the main constituent of the essential oil ofturmeric. Such enhanced bioavailability of curcumin has beendemonstrated in human volunteers. The present invention also relates toan application of curcuminoid with essential oil of turmeric to enhancethe bioavailability of curcumin for oral supplementation against avariety of diseases and method of doing the same. In particular thepresent invention relates to oral supplementation of curcuminoid withessential oil of turmeric to enhance the bioavailability of curcumin forthe prophylaxis, treatment, maintenance therapy and as add on therapyfor disease conditions such as cancer, heart diseases, diabetes,rheumatoid arthritis, osteoarthritis, alzheimer's disease, inflammatorybowel diseases, liver fibrosis and cirrhosis, abdominal aorticaneurysms, HIV, pancreatitis, drug-resistant malaria, psoriasis, cysticfibrosis, epilepsy, wound healing, diseases of the central nervoussystem, chronic degenerative diseases and potentially many otherdiseases where better delivery of curcumin from the supplement to theblood and tissues is critical fir the enhanced therapeutic benefit andan improved method of delivering curcumin and ensuring bioavailabilityin humans.

BACKGROUND OF THE INVENTION

Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione]

is the major yellow pigment of turmeric, a commonly used spice, derivedfrom the rhizome of the herb Curcuma longa Linn. In the Indiansubcontinent and Southeast Asia, turmeric has traditionally been used asa treatment for inflammation, skin wounds, and tumors. Clinical activityof curcumin is yet to be confirmed; however, in preclinical animalmodels, curcumin has shown cancer chemo preventive, antineoplastic andanti-inflammatory properties¹. Especially interesting is its ability toprevent the formation of carcinogen-induced intestinal premalignantlesions and malignancies in rat^(2,3) and in the multiple neoplasia(Min/+) mouse⁴, a genetic model of the human disease familialadenomatous polyposis. Curcumin acts as a scavenger of oxygen speciessuch as hydroxyl radical, superoxide anion and singlet oxygen^(5,6,7)and interferes with lipid peroxidations^(8,9). Curcumin suppresses anumber of key elements in cellular signal induction pathways pertinentto growth, differentiation and malignant transformations. Amongsignaling events inhibited by curcumin are protein kinases¹⁰, c-Jun/AP-1activation¹¹, prostaglandin biosynthesis¹² and activity and expressionof the enzyme cyclooxygenase-2^(13,14). This latter property is probablymediated by the ability of curcumin to block activation of thetranscription factor NF-κB at the level of the NF-κB inducingkinase/IKKα/β signalling complex¹⁵.

Curcumin directly inhibits cyclooxygenase-2 and also inhibits thetranscription of the gene responsible for its production.Cyclooxygenases (COX) catalyze the synthesis of prostaglandins (PGs)from arachidonic acid. There are two isoforms of COX, designated COX-1and COX-2. COX-1 is expressed constitutively in most tissues and appearsto be responsible for housekeeping functions¹⁶ while COX-2 is notdetectable in most normal tissues but is induced by oncogenes, growthfactors, carcinogens and tumor promoters^(17,18,19). Several differentmechanisms account for the link between COX-2 activity andcarcinogenesis.

Curcumin is not simply an alternative to non-steroidal anti-inflammatorydrugs (NSAIDS), which also have anti-inflammatory and cancerchemopreventive properties. This is so because COX is a bifunctionalenzyme with cyclooxygenase and peroxidase activities. Aside from beingimportant for PG synthesis, the peroxidase function contributes to theactivation of procarcinogens. Therefore, the failure of NSAIDS toinhibit the peroxidase function of COX potentially limits theireffectiveness as anticancer agents. Curcumin, in contrast,down-regulates levels of COX-2 and thereby decreases both thecyclooxygenase and peroxidase activities of the enzyme.

Curcumin is among the few agents to block both the COX and LOX(lipoxygenase) pathways of inflammation and carcinogenesis by directlymodulating arachidonic acid metabolism. In a study to evaluate theeffect of curcumin on the metabolism and action of arachidonic acid inmouse epidermis, it was found that topical application of curcumininhibited arachidonic acid-induced ear inflammation in mice²⁰. Curcumin(10 μM) inhibited the conversion of arachidonic acid to 5- and8-hydroxyeicosatetraenoic acid by 60% and 51%, respectively (LOXpathway) and the metabolism to PGE2, PGF2α and PGD2 by 70%, 64% and 73%,respectively (COX pathway). In another study, dietary administration of0.2% curcumin to rats inhibited azoxymethane-induced coloncarcinogenesis and decreased colonic and tumor phospholipase A2,phospholipase Cγ1, and PGE2 levels²¹. In this study, dietary curcuminalso decreased enzyme activity in the colonic mucosa and tumors for theformation of PGE2, PGF2α, PGD2, 6-keto-PGF2α and thromboxane B2 via theCOX system and production of 5(S)-, 8(S)-, 12(S)-, and15(S)-hydroxy-eicosatetraenoic acid via the LOX pathway was alsoinhibited.

Despite this impressive array of beneficial bioactivities, thebioavailability of curcumin in animals and man remains low. In rodents,curcumin demonstrates poor systemic bioavailability after p.o. dosing²²which may be related to its inadequate absorption and fast metabolism.Curcumin bioavailability may also be poor in humans as seen from theresults of a recent pilot study of a standardized turmeric extract incolorectal cancer patients²³. Indirect evidence suggests that curcuminis metabolized in the intestinal tract. Curcumin undergoes metabolicO-conjugation to curcumin glucuronide and curcumin sulfate andbioreduction to tetrahydrocurcumin, hexahydrocurcumin andhexahydrocurcuminol in rats and mice in vivo^(24,25) in suspensions ofhuman and rat hepatocytes²⁶ and in human and rat intestine²⁷. Metabolicconjugation and reduction of curcumin was more in human than in ratintestinal tissue. It has been suggested that the intestinal tract playsan important role in the metabolic disposition of curcumin. This isbased predominantly on experiments in which [³H] labeled curcumin wasincubated with inverted rat gut sacs²⁸. This was later confirmed inintestinal fractions from humans and rats. Intestinal mucosa, as well asliver and kidney tissue from the rat, can glucurodinate and sulfatecurcumin, as judged by the analysis of differential amounts of curcuminpresent before and after treatment of tissue extracts withconjugate-hydrolyzing enzymes²⁹. Thus, gut metabolism contributessubstantially to the overall metabolic yield generated from curcumin invivo. In human intestinal fractions, conjugation with activated sulfuricor glucuronic acids was much more abundant, whereas conjugation in humanhepatic tissues was less extensive, than in the rat tissues³⁰.

Although p.o. administered curcumin has poor bioavailability and onlylow or non-measurable blood levels were observed³¹, this route ofadministration inhibits chemically induced skin and livercarcinogenesis^(32,33). Oral administration of curcumin also inhibitsthe initiation of radiation-induced mammary and pituitary tumors³⁴.Similarly, in a study to assess the curcumin levels in the colorectum, adaily dose of 3.6 g curcumin achieves pharmacologically effective levelsin the colorectum with negligible distribution of curcumin outside thegut³⁵.

Earlier Shobha et al³⁶ had observed that administering piperine alongwith curcumin enhances the bioavailability of curcumin. However, thelevel of enhancement was only modest and no curcumin could be detectedafter 3 hours even when supplemented with piperine.

Although some questions remain unanswered regarding the pharmacokineticsof curcumin in humans, there is no denying the fact that considerableproportion of ingested curcumin is excreted through feces and at leastabout one-half of absorbed curcumin is metabolized. The quantity ofcurcumin that reaches tissues outside the gut is probablypharmacologically insignificant. Several studies have failed todemonstrate the positive in vitro results with curcumin in in vivoanimal and human studies due to lack of absorption of curcumin afteroral administration. To provide the clinical benefits, curcumin must beabsorbed from its oral route of administration at a suitable rate, bedistributed in adequate concentration in the blood and remain in thesystem for a sufficient period at an effective concentration level.

SUMMARY

Some embodiments provide a composition of a curcuminoid mixture andadded essential oil of turmeric. In some embodiments, the weight ratioof the curcuminoid mixture to the added essential oil of turmeric rangesfrom about 1:3 to about 99:1. In some embodiments, the curcuminoidmixture includes curcumin, demethoxycurcumin and bisdemethoxycurcumin.In some embodiments, the essential oil of turmeric includesar-turmerone. In some embodiments, the essential oil of turmericincludes about 40-50% ar-turmerone.

Some embodiments provide a method of treating rheumatoid arthritis byadministering a composition having a curcuminoid mixture and addedessential oil of turmeric.

Some embodiments provide a method of reducing visual analogue scale forpain by administering a composition having curcuminoid mixture and addedessential oil of turmeric.

Some embodiments provide a method of decreasing disease activity scoreby administering a composition having the curcuminoid mixture and addedessential oil of turmeric. Some embodiments provide a method ofimproving patient response to ACR criteria by administering compositionof a curcuminoid mixture and added essential oil of turmeric. Someembodiments provide a method of reducing C-reactive protein levels byadministering a composition of a curcuminoid mixture and added essentialoil of turmeric. Some embodiments provide a method of reducingrheumatoid Arthritis Factor by administering a composition of acurcuminoid mixture and added essential oil of turmeric. Someembodiments provide a method of decreasing joint pain by administering acomposition of a curcuminoid mixture and added essential oil ofturmeric. Some embodiments provide a method of improving walkingdistance scores by administering a composition of a curcuminoid mixtureand added essential oil of turmeric. Some embodiments provide a methodof treating osteoarthritis by administering a composition of acurcuminoid mixture and added essential oil of turmeric. Someembodiments provide a method of treating Alzheimer's disease byadministering a composition of a curcuminoid mixture and added essentialoil of turmeric. Some embodiments provide a method of improving minimental state exam scores by administering a composition of a curcuminoidmixture and added essential oil of turmeric. Some embodiments provide amethod of increasing Vitamin E levels by administering a composition ofa curcuminoid mixture and added essential oil of turmeric. Someembodiments provide a method of increasing serum amyloid beta levels byadministering a composition of a curcuminoid mixture and added essentialoil of turmeric. Some embodiments provide a method of disaggregatingamyloid beta by administering a composition of a curcuminoid mixture andadded essential oil of turmeric. Some embodiments provide a method oflowering plasma isoprostane levels by administering a composition of acurcuminoid mixture and added essential oil of turmeric. Someembodiments provide a method of treating depression by administering acomposition of a curcuminoid mixture and added essential oil ofturmeric. Some embodiments provide a method of improving response rateon Hamilton Depression rate scale by administering a composition of acurcuminoid mixture and added essential oil of turmeric. Someembodiments provide a method if improving clinical global impression byGlobal Severity comprising administering a composition of a curcuminoidmixture and added essential oil of turmeric. Some embodiments provide amethod of improving clinical global impression by Global Change scale byadministering a composition of a curcuminoid mixture and added essentialoil of turmeric.

BRIEF DESCRIPTION OF THE DRAWINGS

The above objectives and advantages of the disclosed teachings willbecome more apparent by describing in detail preferred embodimentsthereof with reference to the attached drawings in which:

FIG. 1 provides a graph showing the bioavailability of curcumin inhumans upon administration of (1) gelatin capsules, which were preparedby admixing curcuminoid isolated from turmeric with essential oil ofturmeric, and, (2) gelatin capsules of curcuminoid alone, which wereprepared without adding essential oil of turmeric to the curcuminoidisolated from turmeric. The x-axis shows time in hours followingadministration of the gelatin capsules. The y-axis shows theconcentration of curcumin (ng/g) in blood

FIG. 2 provides a graph showing the bioavailability of curcumin in humanupon administration of 1) gelatin capsule, which were prepared byadmixing curcuminoid with added essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio, 2) gelatin capsules of curcuminoid alone,which were prepared without adding essential oil of turmeric to thecurcuminoid isolated from turmeric, 3) gelatin capsules of raw turmericpowder alone, 4) gelatin capsules of Essential oil of turmeric with 45%Ar-turmerone alone, 5) gelatin capsules of essential oil of turmericwith 10-15% Ar-turmerone alone, 6) gelatin capsule, which were preparedby admixing curcuminoid with added essential oil of turmeric with 45%Ar-turmerone in 12:1 ratio, The x-axis shows time in hours and y-axisshows the concentration of curcumin (ng/g) in blood

FIG. 3 provides a comparison of the bioavailability of curcumin from thecurcuminoid mixture without added essential oil of turmeric group andthe curcuminoid mixture with added essential oil of turmeric with 45%Ar-turmerone in a weight ratio ranging from about 1:3 to 99:1. Thex-axis shows the ratio of curcumin to essential oil of turmeric andy-axis shows the AUC value of curcumin

FIG. 4 provides a comparison of curcumin bioavailability from 10:1 and1:10 weight ratios of 1) curcuminoid (454.55 mg) with added essentialoil of turmeric (45.45 mg) with 45% Ar-turmerone in 10:1 ratio, 2)curcuminoid (20 mg) with added essential oil of turmeric (2 mg) with 45%Ar-turmerone in 10:1 ratio, 3) curcuminoid (20 mg) with added essentialoil of turmeric (200 mg) with 45% Ar-turmerone in 1:10 ratio, 4)curcuminoid (20 mg) with added essential oil of turmeric (200 mg) with10-15% Ar-turmerone in 1:10 ratio, 5) curcuminoid alone (454.55 mg), 6)curcuminoid alone (20 mg), 7) Essential oil of turmeric with 45%Ar-turmerone alone (45.45 mg), 8) Essential oil of turmeric with 10-15%Ar-turmerone alone (200 mg). The x-axis shows time in hours and y-axisshows the concentration of curcumin (ng/g) in blood

FIG. 5 provides Method of preparation of Essential oil of turmeric withvarying concentration of Ar-turmerone.

FIG. 6 provides Table 9 (ACR response of different groups)

FIG. 7 provides Table 12 (Joint pain measurements and % response ofpatients in each group over 3 months)

FIG. 8 provides Table 13 (Joint line tenderness and % response ofpatients in each group over 3 months)

FIG. 9 provides Table 14 (Walking distance scores and % response ofpatients in each group over 3 months)

DETAILED DESCRIPTION

The disclosure relates to a product to enhance the bioavailability ofcurcumin by mixing a suitable portion of the volatile oil obtained fromturmeric with the curcuminoids isolated from turmeric.

As disclosed herein the term “curcuminoid” is a mixture of curcumin,demethoxycurcumin and bisdemethoxycurcumin. In some embodiments,curcumin is the major component of the curcuminoid mixture. In someembodiments, demethoxycurcumin and bisdemethoxycurcumin are minorcomponents of the curcuminoid mixture. In some embodiments, 95% of thecrystals having curcuminoid mixture are composed of curcumin,demethoxycurcumin and bisdemethoxycurcumin.

The term “essential oil” or “essential oil of turmeric” is also referredto as “volatile oil” or “volatile oil of turmeric.” The essential oil ofturmeric is a mixture of oils. Essential oil is obtained as a by-productduring the extraction of curcumin or curcuminoids from turmeric. In someembodiments, Ar-turmerone, which is also referred to as turmerone, isthe main constituent of essential oil. In some embodiments, Ar-turmeroneconstitutes about 40-50% of the essential oil of turmeric. In someembodiments, Ar-turmerone comprises about 45% of the essential oil ofturmeric.

As stated herein, the term “a” or “an” refers to one or more.

As stated herein, the terms “isolated” and “purified” are referred tointerchangeably.

The volatile oil of turmeric was isolated by conventional methods ofsteam distillation to isolate essential oils and is well known in theart.

Curcumin is isolated from the de-oiled turmeric by solvent extraction.Suitable solvents for this purpose include acetone, hexane, ethylacetate, dicholoroethane, chloroform, etc. The extraction isconveniently carried out at moderate temperatures (40-55° C.) and thesolvent is partially removed to yield a concentrate containing 30-60%solids. This solution is cooled to obtain crystals of curcuminoid whichare isolated by any suitable method such as filtration orcentrifugation. Analysis of this product, which is composed of theisolated crystals of curcumioid mixture, showed that, in someembodiments, 95% of the product was composed of curcumin,demethoxycurcumin and bisdemethoxycurcumin.

The disclosure provides a composition having curcuminoid and anessential oil of turmeric. Curcumin and the volatile oils of curcuminare mixed and blended to get a uniform product. If small percentages(˜5%) of the essential oil of turmeric are added to the curcuminoid,then the bioavailability of curcumin is significantly enhanced.Accordingly, a composition of curcuminoid admixed with a suitableproportion of Ar-turmerone (the main component of the turmeric essentialoil) is provided.

In some embodiments, the weight ratio of the curcuminoid to theessential oil of turmeric ranges from about 1:1 to about 90:1. In someembodiments, the weight ratio of the curcuminoid to the essential oil ofturmeric ranges from about 1:1 to about 3:1. The weight ratio of thecurcuminoid to the essential oil of turmeric can be varied from about3:1 to about 99:1. In some embodiments, the weight ratio of thecurcuminoid to the essential oil of turmeric ranges from about 1:1 toabout 70:1. In some embodiments, the weight ratio of the curcuminoid tothe essential oil of turmeric ranges from about 1:1 to about 45:1. Insome embodiments, the weight ratio of the curcuminoid to the essentialoil of turmeric ranges from about 3:1 to about 50:1. In someembodiments, the weight ratio of the curcuminoid to the essential oil ofturmeric ranges from about 8:1 to about 25:1. In some embodiments, theweight ratio of the curcuminoid to the essential oil of turmeric isabout 90:7. In some embodiments, the weight ratio of the curcuminoid tothe essential oil of turmeric is about 90:8. In some embodiments, theweight ratio of the curcuminoid to the essential oil of turmeric isabout 90:9. In some embodiments, the weight ratio of the curcuminoid tothe essential oil of turmeric is about 89:9. In some embodiments, theweight ratio of the curcuminoid to the essential oil of turmeric isabout 89:8. In one embodiment, the ratio is about 85:15. In anotherembodiment, the ratio is about 92:8. In another embodiment, the ratio isabout 95:5. In another embodiment the weight ratio is about 10:1. Insome embodiments, the weight ratio is about 12:1. In some embodiments,the weight ratio of the curcuminoid to the essential oil of turmeric isabout 1:2. In some embodiments, the weight ratio of the curcuminoid tothe essential oil of turmeric is about 2:1. In some embodiments, theweight ratio of the curcuminoid to the essential oil of turmeric rangesfrom about 1:3 to about 99:1. In some embodiments of the compositionhaving curcuminoid and added essential oil of turmeric, the curcuminoidranges, by weight, from about 24% to about 96%. In some embodiments ofthe composition having curcuminoid and added essential oil of turmeric,the curcuminoid ranges, by weight, from about 30% to about 96%. In someembodiments of the composition of curcuminoid and added essential oil ofturmeric, the curcuminoid ranges, by weight, from about 40% to about75%. In some embodiments of the composition having curcuminoid and addedessential oil of turmeric, the curcuminoid ranges, by weight, from about50% to about 60%.

In some embodiments of the composition having curcuminoid and addedessential oil of turmeric, the demethoxycurcumin ranges, by weight, fromabout 5% to about 25%. In some embodiments of the composition havingcurcuminoid and added essential oil of turmeric, the demethoxycurcuminranges, by weight, from about 10% to about 20%.

In some embodiments of the enhanced curcumin bioavailability compositionhaving curcuminoid and added essential oil of turmeric, thebisdenmethoxycurcumin ranges, by weight, from about 2% to about 7%.

In some embodiments of the enhanced curcumin bioavailability compositionhaving curcuminoid and added essential oil of turmeric, the essentialoil of turmeric ranges, by weight, from about 4% to about 50%. In someembodiments, of the composition of curcuminoid and added essential oilhaving turmeric, the essential oil of turmeric ranges, by weight, fromabout 15% to about 50%. In some embodiments of the composition havingcurcuminoid and added essential oil of turmeric, the essential oil ofturmeric ranges, by weight, from about 20% to about 50%. In someembodiments of the composition having curcuminoid and added essentialoil of turmeric, the essential oil of turmeric ranges, by weight, fromabout 25% to about 40%.

Some embodiments include a composition having a curcuminoid and an addedamount of essential oil of turmeric, wherein the essential oil ispresent in an amount sufficient to cause an enhancement ofbioavailability of the curcumin when administered to a human as comparedto the bioavailability of curcumin upon administration of a compositionprepared using curcuminoid alone without adding essential oil. Curcuminlevels in blood samples is greater following administration of acomposition having curcuminoid and added essential oil of turmeric ascompared to a composition of curcuminoid alone. In some embodiments, theenhancement of bioavailability of curcumin following administration of acomposition of curcuminoid and added essential oil of turmeric rangesfrom about 5-fold to about 16-fold. Enhancement of bioavailability ofcurcumin from a composition prepared by mixing curcuminoid and essentialoil of turmeric is provided in FIG. 1 and Example 1.

In some embodiments, a composition of a curcuminoid and added essentialoil of turmeric is orally administered to a human.

A method of extraction of curcuminoids includes treating dried andpowdered rhizomes of turmeric with a solvent, followed by solventstripping, and steam distilling to obtain an essential-oil free extract.The essential oil-free extract is cooled to about 4° C. to allow thecurcuminoids to crystallize. The curcuminoids are then separated byfiltration, centrifugation or any other method of solid-liquidseparation well-known in the art. In some embodiments, 95% of theseparated crystals are composed of curcumin, demethoxycurcumin andbisdemethoxycurcumin.

Curcumin is isolated from the de-oiled turmeric by solvent extraction.Suitable solvents for this purpose include acetone, hexane, ethylacetate, dicholoroethane, chloroform, etc. The extraction isconveniently carried out at moderate temperatures (about 40° C. to about55° C.) and the solvent is partially removed to yield a concentratecontaining 30-60% solids. This solution is cooled to obtain crystalshaving curcuminoid mixture which are isolated by any suitable methodsuch as filtration or centrifugation. 95% of this product (crystals) wascomposed of the curcuminoid mixture. The remaining may contain traces ofessential oil plus other constituents such as carbohydrates, etc, whichwere not characterized.

The disclosure provides a method of extracting a curcuminoid fromturmeric including:

drying rhizomes of turmeric to form a dried turmeric;

powdering the dried turmeric to form a powdered turmeric;

treating the powdered turmeric with a solvent selected from the groupconsisting of ethyl acetate, acetone, hexane, ethylene dichloride, ethylalcohol, and combinations thereof to form a solution;

stripping the solvent from the solution to form an extract;

cooling the extract to about 4° C. to form crystals and a liquid,wherein the liquid comprises the essential oil of turmeric and a resin;and

separating the crystals from the liquid to obtain the curcuminoidcrystals.

In some embodiments, curcumin, demethoxycurcumin andbisdemethoxycurcumin comprise 95% of the curcuminoid crystals.

Some embodiments include a method of extracting a curcuminoid fromturmeric by drying rhizomes of turmeric to form dried turmeric. Thedried turmeric is powdered to form powdered turmeric. The powderedturmeric is treated with a solvent selected from the group consisting ofethyl acetate, acetone, hexane, and combinations thereof to form asolution. The solvent is stripped from the solution to form an extract.The extract is cooled to about 4° C. to form crystals having curcuminoidmixture, and, a liquid. The liquid comprises the essential oil ofturmeric and a resin. The crystals having the curcuminoid mixture areseparated from the liquid. In some embodiments, 95% of the crystalshaving the curcuminoid mixture is composed of the curcuminoid mixture,namely, curcumin, demethoxycurcumin and bisdemethoxycurcumin.

The volatile oil of turmeric was isolated by conventional methods ofsteam distillation to isolate essential oils and is well known in theart.

Curcuminoid and the essential oil are blended in a suitable proportionby a process including, suspending the curcuminoid in about 3 to 5 timesits quantity of water, mixing in the essential oil, pulverizing in acolloidal mill into fine slurry, and stripping the slurry off waterunder heat and vacuum to obtain a uniform blend. Five hundred milligramcapsules are made from this blend for human consumption.

The disclosure provides a method of preparing a composition including acurcuminoid and an essential oil of turmeric including:

suspending the curcuminoid in water to form a suspension;

adding the essential oil to the suspension to form a mixture;

homogenizing the mixture to obtain a fine slurry; and

drying the fine slurry under heat and vacuum to form a uniform blend ofa composition including the curcuminoid and the essential oil ofturmeric. Drying of the fine slurry under heat and vacuum can beperformed using a vaccumized desolventiser with a stirrer.

A composition of curcuminoid and added essential oil of turmeric can beprepared by suspending the curcuminoid in water to form a suspension.Essential oil is added to the suspension to form a mixture. The mixtureis homogenized to form fine slurry. The fine slurry is dried under heatand vacuum to form a uniform blend of a composition of curcuminoid andan essential oil of turmeric. The fine slurry can be dried under heatand vacuum using, for example, a vaccumized desolventiser having astirrer.

In one embodiment, a homogeneous mixture of curcuminoid and water isprepared by suspending the curcuminoid in water to form a suspension.The suspension is homogenized to obtain fine slurry. The fine slurry isdried under heat and vacuum to form a composition having a homogeneousmixture of the curcuminoid and water.

The disclosure provides a method of preparing a homogeneous mixturehaving a curcuminoid and water by,

suspending a curcuminoid in water to form a suspension;

homogenizing the suspension to obtain a fine slurry; and

drying the suspension under heat and vacuum to form a compositionincluding a homogeneous mixture of the curcuminoid and water.

Hard gelatin capsules, which contain about 500 mg of a blend ofcurcuminoid and essential oil of turmeric, are prepared. A 500 mgcapsule for enhanced bioavailability of curcumin, having the curcuminoidmixture and essential oil of turmeric in a weight ratio of about 95:5 isexpected to contain about 460 mg of curcuminoid and about 40 mg ofessential oil. The curcuminoid mixture is composed of curcumin.demethoxycurcumin and bisdemethoxycurcumin. In terms of activeconstituents, the respective figures would be about 437 mg of curcuminand about 18 mg of Ar-turmerone. In some embodiments, the gelatincapsules have about 300 mg to about 460 mg of curcuminoid and about 40mg to about 375 mg of essential oil of turmeric. In some embodiments ofthe composition having curcumin and added essential oil of turmeric,wherein the gelatin capsule comprises 500 mg of a blend including thecurcuminoid and the essential oil, the curcuminoid in the blend rangesfrom about 300 mg to about 485 mg, and the Ar-turmerone in the blendranges from about 5 mg to about 200 mg.

Gelatin capsules with curcuminoid alone but without added essential oilwere similarly prepared to study the comparative efficacies of thecapsule containing added essential oil versus the capsule preparedwithout adding essential oil.

The disclosure provides a method of preparing a gelatin capsule having acurcuminoid and an essential oil of turmeric by suspending a curcuminoidin water to form a suspension. Then adding an essential oil to thesuspension to form a mixture. Then homogenizing the mixture to obtain afine slurry. Then drying the slurry under heat and vacuum to form auniform blend of a composition having the curcuminoid and the essentialoil of turmeric. Then compressing the blend into the hard gelatincapsule.

Hard gelatin capsules of a composition having a curcuminoid and an addedessential oil of turmeric can be prepared by compressing a uniform blendof the composition into a capsule. Gelatin capsules are prepared bystandard methods using instrument such as a capsule filling machinemanufactured by Pam Pharmaceuticals, Mumbai, India.

The disclosed compositions can be administered to a human for treatingconditions including various human cancers such as colon cancer,prostate cancer, breast cancer, lung cancer, oral cancers, leukemias,etc, diabetes, depression, epilepsy, and various chronic inflammatorydiseases such as rheumatoid arthritis, Alzheimer's disease, inflammatorybowel diseases (Crohn's disease, ulcerative colitis), coronary arterydiseases, fibrosis and cirrhosis of liver, pancreatitis, abdominalaortic aneurysms, drug-resistant malaria, psoriasis, cystic fibrosis.HIV, wound healing, central nervous system disorders and potentiallymany other diseases. Another embodiment of the present inventionprovides for an application of a formulation of curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 10:1 ratio for oralsupplementation against rheumatoid arthritis and an improved method ofdelivering curcumin in human blood and tissues and ensuring betterbioavailability in humans for the prophylaxis and treatment for activerheumatoid arthritis patients, maintenance therapy for preventing flareup of symptoms and as add on therapy with antiarthritic medications. Insome embodiments, the ratio of curcuminoid mixture to essential oil ofturmeric is 12:1 ratio for oral supplementation against rheumatoidarthritis and an improved method of delivering curcumin in human bloodand tissues and ensuring better bioavailability in humans for theprophylaxis and treatment for active rheumatoid arthritis patients,maintenance therapy for preventing flare up of symptoms and as add ontherapy with antiarthritic medications. Raw turmeric powder, essentialoil of turmeric with 45% Ar-turmerone, essential oil of turmeric with10-15% Ar-turmerone, curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 1:10 ratio, curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 1:1 ratio, curcuminoid 24% with essential oilof turmeric with 45% Ar-turmerone in 10:1 ratio, curcuminoid withessential oil of turmeric with 10-15% Ar-turmerone in 10:1 ratio,formulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio, curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 12:1 ratio or curcuminoids 95% were given topatients with active rheumatoid arthritis for 2 months duration in adose of 500 mg capsules twice daily. Formulation of curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 10:1 and 12:1 ratioswere able to significantly decrease disease activity score, total numberof swollen and painful joints and erythrocyte sedimentation rate. Thepatients administered formulation of Curcuminoid with essential oil ofturmeric with 45% Ar-turmerone in 10:1 and 12:1 ratios, also showedsignificant improvement when assessed according to the American Collegeof Rheumatology criteria, functional status and pain score. Theinflammatory marker C reactive protein (CRP), anti streptolysin O (ASO)values and rheumatoid arthritis factor (RA) also drastically decreasedin patients taking formulation of curcuminoid with essential oil ofturmeric with 45% Ar-turmerone in 10:1 and 12:1 ratios. Similar benefitswere not evidenced in any of the patients given curcuminoids 95% alonein similar dose. The patients who were given maintenance therapy offormulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 10:1 and 12:1 ratios alone after 2 months continued tobe asymptomatic during the follow up phase of 4 more months.

Another embodiment of the present invention provides for application ofa formulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio for oral supplementation againstosteoarthritis and an improved method of delivering curcumin in thehuman blood and tissues and ensuring bioavailability in humans for theprophylaxis and treatment for osteoarthritic patients, maintenancetherapy for preventing flare up of symptoms and as add on therapy withantiarthritic medications. In some embodiments, the ratio of curcuminoidmixture to essential oil of turmeric is 12:1 ratio for oralsupplementation against osteoarthritis and an improved method ofdelivering curumin in the human blood and tissues and ensuringbioavailability in humans for the prophylaxis and treatment forosteoarthritic patients, maintenance therapy for preventing flare up ofsymptoms and as add on therapy with antiarthritic medications.Osteoarthritic patients were given Raw turmeric powder, essential oil ofturmeric with 45% Ar-turmerone, essential oil of turmeric with 10-15%Ar-turmerone, curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 1:10 ratio, curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 1:1 ratio, curcuminoid 24% with essential oilof turmeric with 45% Ar-turmerone in 10:1 ratio, curcuminoid withessential oil of turmeric with 10-15% Ar-turmerone in 10:1 ratio,formulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio. Curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 12:1 ratio, and curcuminoids 95% in a dose of500 mg twice daily for 3 months. Almost all patients in formulation ofcurcuminoid with essential oil of turmeric with 45% Ar-turmerone in 10:1and 12:1 ratio group had significant improvement in the jointtenderness, crepitus, joint swelling, range of movements and gait. Inthe group given curcuminoids 95%, majority of patients remainedsymptomatic throughout the study and had to be started on analgesicdrugs and antiarthritic medications before the end of the study.

Another embodiment of the present invention provides for application offormulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio for oral supplementation in patients withAlzheimers disease and an improved method of delivering curcumin in thehuman blood and tissues and ensuring bioavailability in humans to delaythe onset of neurodegenerative diseases like Alzheimers disease, fortreatment and symptomatic improvement in patients with Alzheimersdisease. In some embodiments, the ratio of curcuminoid mixture toessential oil of turmeric is 12:1 ratio for oral supplementation inpatients with Alzheimers disease and an improved method of deliveringcurcumin in the human blood and tissues and ensuring bioavailability inhumans to delay the onset of neurodegenerative diseases like Alzheimersdisease, for treatment and symptomatic improvement in patients withAlzheimers disease. Alzheimers disease patients were given raw turmericpowder, essential oil of turmeric with 45% Ar-turmerone, essential oilof turmeric with 10-15% Ar-turmerone, curcuminoid with essential oil ofturmeric with 45% Ar-turmerone in 1:10 ratio, curcuminoid with essentialoil of turmeric with 45% Ar-turmerone in 1:1 ratio, curcuminoid 24% withessential oil of turmeric with 45% Ar-turmerone in 10:1 ratio,curcuminoid with essential oil of turmeric with 10-15% Ar-turmerone in10:1 ratio, formulation of curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 10:1 ratio, Curcuminoid with essential oil ofturmeric with 45% Ar-turmerone in 12:1 ratio or curcuminoids 95% in adose of 3 gm/day. The patients on curcuminoid with essential oil ofturmeric with 45% Ar-turmerone in 10:1 and 12:1 ratio formulationssignificantly benefitted cognitive performance, functional impairment,behavior and global function compared with commercial curcuminformulation in the same dose. The serum level of Amyloid beta increasedsignificantly in group taking the formulation of curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 10:1 and 12:1 ratiosreflecting the ability of formulation of curcuminoid with essential oilof turmeric with 45% Ar-turmerone in 10:1 and 12:1 ratios todisaggregate Amyloid beta deposits in the brain compared to curcuminoids95%. It was also associated with an increase in the Vitamin E contentbetween curcuminoids 95% and formulation of curcuminoid with essentialoil of turmeric with 45% Ar-turmerone in 10:1 and 12:1 ratios, thevalues being significantly higher for the formulation of curcuminoidwith essential oil of turmeric with 45% Ar-turmerone in 10:1 and 12:1ratio groups. Another human study which supplemented formulation ofcurcuminoid with essential oil of turmeric with 45% Ar-turmerone in 10:1and 12:1 ratios to patients with mild cognitive impairment over a periodof 2 years showed that the risk of development of dementia andAlzheimers disease is reduced drastically in all patients on formulationof curcuminoid with essential oil of turmeric with 45% Ar-turmerone in10:1 and 12:1 ratios therapy while majority of the patients incurcuminoids 95% progressed to dementia and 50% to Alzheimers diseasewithin 2 years.

Another embodiment of the present invention provides for application ofa formulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 10:1 and 12:1 ratios for oral supplementation inpatients with depression and an improved method of delivering curcuminin the human blood and tissues and ensuring bioavailability in humansfor treatment of patients with depression. Patients with depression weregiven raw turmeric powder, essential oil of turmeric with 45%Ar-turmerone, essential oil of turmeric with 10-15% Ar-turmerone,curcuminoid with essential oil of turmeric with 45% Ar-turmerone in 1:10ratio, curcuminoid with essential oil of turmeric with 45% Ar-turmeronein 1:1 ratio, curcuminoid 24% with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio, curcuminoid with essential oil of turmericwith 10-15% Ar-turmerone in 10:1 ratio, formulation of curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 10:1 ratio,curcuminoid with essential oil of turmeric with 45% Ar-turmerone in 12:1ratio and curcuminoids 95% in a dose of 500 mg twice daily for 8 weeks.Almost all patients in formulation of curcuminoid with essential oil ofturmeric with 45% Ar-turmerone in 10:1 and 12:1 ratio groups hadsignificant reduction in the severity of depression as assessed by theHamilton depression scale and showed significant reduction in severityof illness and improvement and response to treatment as assessed by theclinical global impression scale. The inventive compositions have theadditional benefit that the essential oil components are themselvesbioactive (for example, see Yue, A et al, int. J. Mol. Med., 2002,9:481-84; Jayaprakasha, G. K. et al, Z. Naturforsch., 2002, 57:828-35)and thus are expected to synergistically enhance the bioactivity ofcurcumin.

It will be readily understood by the skilled artisan that numerousalterations may be made to the examples and instructions given herein.These and other objects and features of present invention will be madeapparent from the following examples. The following examples asdescribed are not intended to be construed as limiting the scope of thepresent invention.

EXAMPLES Example 1

Nine healthy human volunteers aged between 25 and 45 years of age wereselected for the study. They were given capsules of curcuminoid mixturealone and capsules of enhanced curcumin capsules at the dosage of 50 mgcurcuminoid/kg body weight. Enhanced curcumin is a composition havingcurcuminoid and added essential oil of turmeric. In the enhancedcurcumin capsules the weight ratio of curcuminoid to essential oil ofturmeric was 10:1. The subjects were advised to take curcuminoidcapsules first. Blood samples were collected at zero hour andperiodically at one-hour or half-hour intervals for 8 hours. After awashout period of one week, the same protocol was repeated with enhancedcurcumin bioavailability capsules. The whole blood was extractedexhaustively with ethyl acetate to recover curcumin. The ethyl acetateextract was analyzed by HPLC on a RP-C18 column (25×4.5 mm) usingtetrahydrofuran (THF) as solvent and UV detection at 420 nm. The eluantflow rate was 1 ml/min. Efficiency of the extraction procedure forrecovering curcumin from blood samples was determined by measuringrecovery of curcumin upon extraction of normal blood samples. Normalblood samples were collected by adding curcumin to normal blood (ofpersons not consuming curcumin or enhanced curcumin capsules). Curcuminwas extracted from the normal blood samples by the above procedure. Theefficiency of recovery of curcumin by the above extraction procedure wasestimated to range between 80.12% and 86.49%.

A typical result is given in Table 1.

TABLE 1 Curcumin content in blood (ng/g) Enhanced curcumin Curcuminbioavailability Time (h) composition composition 0.0 0.0 0 0.5 3.17 7.851.0 7.57 6.23 1.5 4.42 4.84 2.0 13.81 11.95 2.5 9.61 19.22 3.0 5.6792.59 4.0 8.2 24.33 6.0 1.62 8.43 8.0 1.11 5.09The results are also graphically represented in FIG. 1. Followingadministration of capsules having a 10:1 weight ratio of curcuminoid toessential oil of turmeric, the peak absorption of curcumin occurred at 3hr. Furthermore, curcumin persisted in small amounts in the blood till 8hr beyond which measurements were not made. At peak absorption theenhancement of bioavailability ranged, among the 9 persons, between 5and 16-fold with a mean value of 10.62.

Example 2

Human subjects were administered capsule (4×500 mg) prepared withcurcuminioids and without added essential oil of turmeric (curcuminoidsgroup in Table 2). Blood was drawn at different intervals (one hour) andtested for curcumin content. After two weeks the same groups wereadministered an enhanced curcumin bioavailability composition (4×500mg). The varying ratios of curcuminoids and added essential oil ofturmeric are as provided in Table 2. Blood from the enhanced curcumingroup was drawn at different intervals and tested for curcumin content.As seen in Table 2, bioavailability of curcumin was greater whenenhanced curcumin capsules were administered as compared toadministration of capsule containing curcuminoids without addedessential oil of turmeric.

TABLE 2 Analysis of curcumin content in blood. Ratio of curcuminoids toCurcumin content in blood (AUC) added essential oil of Curcuminoidmixture Enhanced turmeric alone group curcumin group 90:4 725 5147.590:5 820 5904 90:6 750 5475 90:7 900 6300.0 90:8 752 5367.6 90.9 7825552.2 89.9 696 5080.8  90:10 760 5320 80:9 726 5227.2  80:20 754 5315.7 90:20 765 5469.75  70:20 810 5147.5The ratios of curcuminoids to added essential oil of turmeric in theenhanced curcumin bioavailability composition provided in Table 2 canalso be represented as shown in Table 3. The unit of curcumin content inblood is provided as area under the curve (AUC).

TABLE 3 Ratio of curcuminoids to added essential oil in compositions forenhanced curcumin bioavailability Ratio of Curcuminoids to added Ratioof curcuminoids to added essential oil of turmeric essential oil ofturmeric 90:4 22.5:1  90:5  18:1 90:6  15:1 90:7 12.9:1 90:8 11.25:1 90:9 10:1  90:10   9:1 80:9 8.9:1  80:20   4:1  90:20 4.5:1  70:20 3.5:1

Example 3

Bioavailability of Curcumin from Essential Oil of Turmeric Alone, RawTurmeric Powder, Curcuminoid Alone, Curcuminoid with Essential Oil ofTurmeric with 45% Ar-Turmerone in 10:1 Ratio and Curcuminoid withEssential Oil of Turmeric with 45% Ar-Turmerone in 12:1 Ratio Etc.

Nine healthy human volunteers were given capsules containing 475 mg ofcurcuminoid mixture without added essential oil of turmeric (the capsulewas made up to 500 mg by addition of rice powder) at a dosage of 50 mgcurcuminoid/kg body weight. Blood was drawn from the subjects atbaseline, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours post drug. The samesubjects after a washout period of one week were given 500 mg capsulehaving 454.55 mg curcuminoid mixture with 45.45 mg essential oil ofturmeric, wherein the essential oil of turmeric had about 45%Ar-turmerone (the weight ratio of curcuminoid mixture to added essentialoil of turmeric was 10:1) at a dosage of 50 mg curcuminoid/kg bodyweight of the subject. Blood was drawn from the subjects at baseline,0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours post drug. Table 4 provides theamount of curcumin in nanograms per gram of blood for the subjects,which was averaged for each time point.

The above protocol was repeated with the following three formulations:

(1) A capsule having 500 mg of essential oil of turmeric, wherein theessential oil of turmeric had 10-15% Ar-turmerone, was administered at adosage of 50 mg of essential oil of turmeric per kg body weight of thehuman subject;

(2) A capsule having 500 mg of essential oil of turmeric, wherein theessential oil of turmeric had 45% Ar-turmerone, administered at a dosageof 50 mg of essential oil of turmeric per kg body weight of the humansubject; and

(3) A capsule having 500 mg of raw turmeric powder was administered at adosage of 50 mg of raw turmeric powder/kg body weight of the humansubject.

(4) A capsule having 500 mg of 461.5 mg curcuminoid mixture with 38.45mg essential oil of turmeric, wherein the essential oil of turmeric hadabout 45% Ar-turmerone (the weight ratio of curcuminoid mixture to addedessential oil of turmeric was 12:1)

Whole blood drawn from the subjects was extracted exhaustively withethyl acetate to recover curcumin. The ethyl acetate extract wasanalyzed by HPLC on a RP-C18 column (25×4.5 mm) using tetrahydrofuran(THF) as solvent and UV detection at 420 nm. The eluent flow rate was 1ml/min. As seen in Table 4 and FIG. 2, curcumin bioavailability in humansubjects following administration of raw turmeric was low. Curcuminbioavailability following administration of negative controls, namely,essential oil fractions having 10-15% or 45% Ar-turmerone was notdetectable (referred to as Nd in Table 4). Whereas, curcumin wasdetectable in human subjects following administration of curcuminoidmixture without added essential oil of turmeric, the bioavailability ofcurcumin was enhanced by 6.7 fold upon administration of a compositionhaving curcuminoid mixture and essential oil of turmeric with 45% Ar-tin 10:1 ratio and the bioavailability of curcumin was enhanced by 8.3fold upon administration of a composition having curcuminoid mixture andessential oil of turmeric with 45% Ar-t in 12:1 ratio.

As seen in FIG. 2, the maximum concentration of curcumin in blood (Cmaxof curcumin) was 13.81 ng/g upon administration of the negative controlcapsule having curcuminoid mixture without the added essential oil ofturmeric, whereas, the Cmax of curcumin was 92.59 ng/g uponadministration of the positive control capsule having curcuminoidmixture and added essential oil of turmeric with 45% Ar-t in 10:1 ratio.The Cmax of curcumin was 114.59 ng/g upon administration of the positivecontrol capsule having curcuminoid mixture and added essential oil ofturmeric with 45% Ar-t in 12:1 ratio. Therefore, comparison of the Cmaxvalues shows that bioavailability of curcumin upon oral administrationof the claimed composition having curcuminoid mixture and addedessential oil of turmeric with 45% Ar-t in 10:1 was 6.7 times greaterthan bioavailability of curcumin upon oral administration of curcuminoidmixture without the added essential oil of turmeric. Bioavailability ofcurcumin upon oral administration of the claimed composition havingcurcuminoid mixture and added essential oil of turmeric with 45% Ar-t in12:1 ratio was 8.3 times greater than bioavailability of curcumin uponoral administration of curcuminoid mixture without the added essentialoil of turmeric.

TABLE 4 Negative and Positive Control experiments Curcumin content: inblood (ng/g) Curcuminoid Curcuminoid mixture mixture Curcuminoid withadded with added Essential oil Essential oil mixture essential oilessential oil Raw of turmeric of turmeric without added of turmeric ofturmeric Time in turmeric (45% Ar- (10-15% Ar- Essential oil (45% Ar-(45% Ar- hours powder turmerone) turmerone) of turmeric turmerone) 10:1turmerone) 12:1 0 0  0 0 0 0 0 0.5 Nd Nd Nd 3.17 7.85 15.2 1  1.05 Nd Nd7.57 6.23 23.4 1.5 Nd Nd Nd 4.42 4.84 32.8 2 2.1 Nd Nd 13.81 11.95 69.82.5 Nd Nd Nd 9.61 19.22 114.59 3 Nd Nd Nd 5.67 92.59 88.5 4 Nd Nd Nd 8.224.33 49.4 6 Nd Nd Nd 1.62 8.43 20.74 8 Nd Nd Nd 1.11 5.09 10.8

Example 4

Bioavailability of Curcumin from Capsules Having a Weight Ratio ofCurcuminoid Mixture to Essential Oil of Turmeric Ranging from about 1:3to 99:1

Human volunteers aged between 25 and 45 years were randomized intoseparate groups having 3 subjects each (Groups A through W). For controlexperiment, at the initial time point, subjects in all the groups werefour 500 mg capsules of C without added E having about 475 mg ofcurcuminoid mixture. Then blood was drawn from the subjects at differenttime periods (0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours post drug) andthe amount of curcumin in blood (in nanograms per gram of blood) wasdetermined. The average values of curcumin in blood at each time periodwas plotted in separate graphs for each of the groups (A to W). For eachof the groups, the area under the curve (AUC) of curcumin was calculatedfrom the figure. In Table 5 and FIG. 3, AUC is provided as nanograms ofcurcumin per gram of blood.

After a wash out period of 2 weeks, subjects in groups A through W weregiven four 500 mg capsules each, wherein set of 4 capsules had varyingratios of curcuminoid mixture to added essential oil of turmeric(referred to as C with added E capsule in Table 5), and wherein theessential oil of turmeric in the capsules had 45% Ar-turmerone. Theratio of curcuminoid mixture to essential oil of turmeric in thecapsules ranged from about 99:1 to about 1:3. Some of the could beexpressed as more than one type of ratio, for example, as 95:5 or 19:1;90:4 or 22.5:1; 90:5 or 18:1; 90:6 or 15:1; 90:7 or 12.9:1; 90:8 or11.3:1; 90:9 or 10:1; 90:10 or 9:1; 90:20 or 4.5:1; 89:9 or 9.8:1; 80:9or 8.8:1; 80:20 or 4:1; 70:20 or 3.5:1; 75:25 or 3:1; 60:30 or 2:1;50:50 or 1:1, 30:60 or 1:2 and 25:75 or 1:3 and therefore the ratios arereferred to accordingly in Table 5.

As shown in Table 5, each of the groups was administered a capsulehaving a different weight ratio of curcuminoid mixture to essential oilof turmeric (referred to as C:E). Blood was drawn from the subjects andthe AUC was calculated as described above. The curcumin content in theblood for each group was expressed as AUC, which was used to compare thebioavailability of curcumin from the different treatment groups.

Table 5 and FIG. 3 provide a comparison of the bioavailability ofcurcumin from the curcuminoid mixture without added essential oil ofturmeric as the control group and the curcuminoid mixture with addedessential oil of turmeric with 45% Ar-turmerone.

As seen in Table 5 and FIG. 3, curcumin bioavailability uponadministration of capsules having curcuminoid mixture with addedessential oil of turmeric with 45% Ar-turmerone resulted in anenhancement of bioavailability ranging from 1.8 to 7.3 fold over thecurcumin bioavailability that was observed when negative controlcapsules having curcuminoid mixture without added essential oil ofturmeric were administered. The results in Table 5 further show that theenhancement of bioavailability was observed over the entire claimedrange of the ratio about 1:3 to about 99:1 of curcuminoid mixture toessential oil of turmeric.

TABLE 5 Bioavailability of curcumin from compositions having weightratios of curcuminoid mixture to added essential oil of turmeric rangingfrom 1:3 to 99:1 C without added E C with added E C (ng) C (ng) Dosage C(mg) per gm C (mg) E (mg) per gm 4 caps per of blood per per of bloodGroup Ratio of C:E each capsule (AUC) capsule capsule (AUC) A 99:1 500mg 475 771 495 5 3855 B 95:5 or 19:1 500 mg 475 786 475 25 5515 C 90:4or 22.5:1 500 mg 475 725 478.72 21.28 5147.5 D 90:5 or 18:1 500 mg 475820 473.68 26.32 5904 E 90:6 or 15:1 500 mg 475 750 468.75 31.25 5475 F90:7 or 12.9:1 500 mg 475 900 463.77 36.23 6300 G 90:8 or 11.3:1 500 mg475 752 459.35 40.65 5367.6 H 90:9 or 10:1 500 mg 475 782 454.55 45.455552.2 I 90:10 or 9:1 500 mg 475 760 450 50 5320 J 90:20 or 4.5:1 500 mg475 765 409.1 90.9 5469.75 K 89:9 or 9.8:1 500 mg 475 696 453.7 46.35080.8 L 80:9 or 8.8:1 500 mg 475 726 448.98 51.02 5227.2 M 80:20 or 4:1500 mg 475 754 400 100 5315.7 N 70:20 or 3.5:1 500 mg 475 810 388.89111.11 5147.5 O 70:1 500 mg 475 769 493 7 5124 P 60:1 500 mg 475 725491.8 8.2 5200 Q 50:1 500 mg 475 749 490.2 9.8 5284 R 40:1 500 mg 475737 487.8 12.2 5310 S 75:25 or 3:1 500 mg 475 756 375 125 4158 T 60:30or 2:1 500 mg 475 742 333.3 166.6 3635.8 U 50:50 or 1:1 500 mg 475 788250 250 2537 V 30:60 or 1:2 500 mg 475 715 166.6 333.3 1651 W 25:75 or1:3 500 mg 475 726 125 375 1276

Example 5

Comparison of Curcumin Bioavailability from 10:1 and 1:10 Weight Ratiosof Curcuminoid Mixture to Essential Oil of Turmeric

Nine healthy human volunteers were given four 500 mg capsules having 20mg curcuminoid mixture without added essential oil of turmeric (referredto as 20 mg C in Table 6). Blood was drawn from the subjects atbaseline, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours post drug. Followingone week washout period, the same nine subjects were given four 500 mgcapsules having 200 mg of essential oil of turmeric having 10 to 15%Ar-turmerone. Blood was drawn from the subjects at baseline, 0.5, 1,1.5, 2, 2.5, 3, 4, 6 and 8 hours post drug.

With one week washout period between treatments, the subjects weretested for the following treatments, wherein four of 500 mg capsuleswere administered to each subject. If any of the capsules had less than500 mg of the test component such as curcuminoid mixture or essentialoil or the combination of curcuminoid mixture and essential oil, thenthe capsules were made up to 500 mg by addition of a placebo, e.g. ricepowder. In one treatment, each capsule had a 1:10 ratio of curcuminoidmixture to added essential oil of turmeric. Each capsule contained 20 mgcurcuminoid and 200 mg essential oil of turmeric, wherein the essentialoil of turmeric had 10 to 15% Ar-turmerone (referred to as Ar-t in Table6).

In another treatment, each capsule had a 1:10 ratio of curcuminoidmixture to added essential oil of turmeric, wherein the essential oilhad 45% Ar-turmerone. Each capsule contained 20 mg curcuminoid and 200mg essential oil of turmeric. The capsule is referred to as 20 mg C: 200mg E=1:10 (E had 10-15% Ar-t) in Table 6.

In another treatment, the capsule had a 10:1 ratio of curcuminoidmixture to added essential oil of turmeric, wherein the essential oilhad 45% Ar-turmerone. Each capsule contained 20 mg curcuminoid and 2 mgessential oil of turmeric. The capsule is referred to as 20 mg C: 2 mgE=10:1 (E had 45% Ar-t) in Table 6.

In another treatment, each capsule had curcuminoid mixture without theadded essential oil of turmeric. Each capsule contained 454.55 mgcurcuminoids. The capsule is referred to as 454.55 mg C without added Ein Table 6.

In another treatment, each capsule had essential oil of turmeric having45% Ar-turmerone. Each capsule contained 45.45 mg essential oil ofturmeric. The capsule is referred to as 45.45 mg E (45% Ar-t) in Table6.

In another treatment, each capsule had curcuminoid mixture along withadded essential oil of turmeric with 45% Ar-turmerone at a 10:1 ratio.Each capsule contained 454.55 mg curcuminoids and 45.45 mg of essentialoil of turmeric. The essential oil of turmeric had 45% Ar-turmerone. Thecapsule is referred to as 454.55 mg C: 45.45 mg E=10:1 (E had 45% Ar-t)in Table 6.

Whole blood from the subjects was extracted exhaustively with ethylacetate to recover curcumin. The ethyl acetate extract was analyzed byHPLC on a RP-C18 column (25×4.5 mm) using tetrahydrofuran (THF) assolvent and UV detection at 420 nm. The eluent flow rate was 1 ml/min.Curcumin content in the blood was determined for each group at each timepoint and the average value of curcumin in blood (in nanogram per gramof blood) was calculated. The average value of curcumin at each timepoint for various the treatment protocols is provided in Table 6 and inFIG. 4.

As seen in Table 6, low bioavailability of curcumin of about 1.05 ngcurcumin per gm of blood was observed from the negative control having20 mg of curcuminoid mixture without added essential oil of turmeric. Inthe negative controls having essential oil of turmeric alone, witheither 10-15% Ar-turmerone or 45% Ar-turmerone, the bioavailability ofcurcumin was not detectable (referred to as Nd in Table 6). Further,bioavailability of curcumin from the capsule prepared and having a 1:10ratio of curcuminoid mixture to essential oil of turmeric, wherein theessential oil had either a 10-15% Ar-turmerone content or 45%Ar-turmerone content, showed poor bioavailability of curcumin.

An experimental capsule prepared at the ratio of 10:1 of curcuminoidmixture to essential oil of turmeric, wherein the essential oil had a45% Ar-turmerone content, having 20 mg curcuminoid mixture and 2 mgessential oil of turmeric showed greater than 2-told enhancedbioavailability over the negative control of 20 mg curcuminoid mixturewithout the added essential oil of turmeric. On the other hand thepositive control having 454.55 mg curcuminoid mixture and 45.55 mgessential oil of turmeric, wherein the essential oil of turmeric had a45% Ar-turmerone content, i.e., a 10:1 ratio of curcuminoid mixture toessential oil of turmeric, showed a 6.97 fold enhancement ofbioavailability of curcumin as compared to the bioavailability ofcurcumin from the negative control capsule having 454.55 mg curcuminoidmixture without the added essential oil of turmeric.

TABLE 6 Comparison of curcumin bioavailability from 10:1 and 1:10 weightratios of curcuminoid mixture to essential oil of turmeric Nanograms ofcurcumin per gram of blood 20 mg 20 mg 20 mg 454.55 mg C:200 mg C:200 mgC:2 mg C:45.45 mg 200 mg E = 1:10 E = 1:10 E = 10:1, 454.55 45.45 E =10:1 E alone (E had (E had (E had mg C mg E (E had Time 20 (10-15%10-15% 45% 45% without (45% 45% (h) mg C Ar-t) Ar-t) Ar-t) Ar-t) added EAr-t) Ar-t) 0 0   0 0  0  0 0 0 0 0.5 Nd Nd Nd Nd 1.1 3.02 Nd 7.45 1 NdNd Nd Nd 1 7.27 Nd 5.81 1.5 Nd Nd Nd Nd 1.05 4.11 Nd 4.52 2 1.05 Nd 1.11.3 1.3 13.18 Nd 11.46 2.5 Nd Nd Nd 1.1 1.7 9.17 Nd 15.66 3 Nd Nd Nd Nd2.67 5.21 Nd 91.9 4 Nd Nd Nd Nd 1.34 7.82 Nd 22.44 6 Nd Nd Nd Nd 1.11.54 Nd 8.01 8 Nd Nd Nd Nd 1.05 1.05 Nd 6.18

Example 6

Method of Preparation of Curcuminoid Mixture with 95% Curcuminoids

The rhizomes of turmeric (300 Kg) were dried. The dried turmericrhizomes were powdered to form powdered turmeric. The powdered turmericwas treated with ethyl acetate (900 L) to form a solution. Theextraction was carried out at 78° C. temperature for 1 hr. After initialextraction, the extraction process was repeated 4 more times and theresultant solution was filtered and the solvent was stripped from thefiltered solution to form an extract. This extract was cooled to about4° C. to obtain crystals of curcuminoid (12 Kg) and a liquid. Thecrystals of curcuminoid were isolated from the liquid by filtration. Thecrystals were powdered to form powdered curcuminoid mixture with 95%curcuminoids.

Example 7

Method of Preparation of Curcuminoid Mixture with 24% Curcuminoids

The rhizomes of turmeric (50 Kg) were dried and flaked into requiredsize. The flakes of turmeric was filled in the soxhlect apparatus andextracted with ethylene dichloride (EDC). The extraction was carried outfor 5 hrs at a temperature of about 83° C. After the completion ofextraction, the solvent was filtered. The solvent was removed bydistillation and mild vacuum was applied to get an oleoresin whichcontains essential oil of turmeric and curcuminoid. The oleoresin wassteam distilled to get essential oil and a residue. The residue wasdried under vacuum to form a powder (10 Kg) with 24% curcuminoidcontent.

Example 8

Method of Analysis of Total Curcuminoids by HPLC Method

From 500 mg capsule, 25 mg was accurately weighed and transferred into a50 ml standard flask and made up to a 50 ml solution with methanol. Fromthis pipette out 2 ml into 50 ml standard flask and made up to a 50 mlsolution with methanol. Filter through 0.2 μm membrane filter beforeinjection. Standard was prepared by weighing accurately 25 mg standard[Curcumin Standard: −99% Total Curcuminoids (Sigma)] and transferredinto a 50 ml standard flask and made up to a 50 ml solution withmethanol. From this pipette out 2 ml into 50 ml standard flask and madeup to a 50 ml solution with methanol. Filter through 0.2 μm membranefilter before injection.

The total Curcuminoids was analyzed by high performance liquidchromatography (HPLC) on a C18 column ((250×4.6 mm Shimadzu Co., Japan.)using tetrahydrofuran (THF) as the mobile phase and UV detection at 420nm. The eluent flow rate was 1 ml/min.

By comparing the area of standard and sample, the percentage of totalcurcuminoids was calculated using the formula

${\%\mspace{14mu}{of}\mspace{14mu}{total}\mspace{14mu}{Curcuminoid}} = \frac{{Area}\mspace{14mu}{of}\mspace{14mu}{sample} \times {amount}\mspace{14mu}{of}\mspace{14mu}{std} \times {Purity}\mspace{14mu}{of}\mspace{14mu}{std}}{{Area}\mspace{14mu}{of}\mspace{14mu}{Std} \times {weight}\mspace{14mu}{of}\mspace{14mu}{the}\mspace{14mu}{sample}}$

Example 9

Method of Preparation of Essential Oil of Turmeric with VaryingConcentration of Ar-Turmerone

The rhizomes of turmeric (500 Kg) were dried. The dried turmericrhizomes were powdered to form powdered turmeric. The powdered turmericwas treated with ethyl acetate (1500 L) to form a solution. Theextraction was carried out at 78° C. temperature for 1 hr. After initialextraction, the extraction process was repeated 4 more times and theresultant solution was filtered and the solvent was stripped from thefiltered solution to form an extract. This extract was cooled to about4° C. to obtain crystals of curcuminoid (20 Kg) and a liquid. Thecrystals of curcuminoid were isolated from the liquid by filtration.

The remaining liquid comprises the essential oil of turmeric and aresin. The liquid was then steam distilled to isolate essential oil ofturmeric with 10-15% Ar turmerone (25 Kg). After fractionating this oil,essential oil with 45% Ar turmerone (7.5 Kg) was obtained as fraction 3,essential oil of turmeric with 4-5% Ar turmerone (8.3) was obtained asfraction 2 and essential oil of turmeric with 2-3% Ar turmerone (9.3 Kg)was obtained as fraction 1. (FIG. 5)

Example 10

Method of Preparation of Combination of Curcuminoids and Essential Oilof Turmeric with 45% Ar Turmerone in 10:1 Ratio

The curcuminoid powder prepared as per Example 6 (2.7 Kg) was suspendedin water (12 L) to form a suspension. Fraction of essential oilcontaining 45% Ar-turmerone prepared as per Example 9 (0.27 Kg) wasadded to the suspension in 10:1 ratio. The mixture is pulverized in acolloidal mill to form fine slurry. Water is stripped from the slurryunder heat and vacuum to form a uniform blend. (3 Kg).

A 500 mg capsule containing 454.55 mg of curcuminoid and 45.45 mg ofEssential oil with 45% Ar-turmerone in a weight ratio of about 90:9(10:1) was prepared by encapsulating the above blended extract powder inhard gelatin capsules done in an air-conditioned at 21° C. andde-humidified room. 3 kg of extract powder was charged into the hopperof a semi-automatic capsule filling machine. ‘0’ size hard gelatincapsule shell was loaded to the tray and the blended extract powder wasfilled into the shell. The filled weight of capsules were checkedsimultaneously and these capsules were sorted by a sorting machine andpolished with the help of a polishing machine to give 6000 capsules of500 mg each.

Example 11

Method of Preparation of Combination of Curcuminoids and Essential Oilof Turmeric with 45% Ar-Turmerone in 1:10 Ratio

The powdered curcuminoid mixture prepared as per Example 6 (0.27 Kg) wassuspended in water (1 L) to form a suspension. Fraction of essential oilof turmeric containing 45% Ar-turmerone prepared as per Example 9 (2.7Kg) was added to the suspension in 1:10 ratio. The mixture is pulverizedin a colloidal mill to form fine slurry. Water was stripped from theslurry under heat and vacuum to form a uniform blend (3 Kg).

Capsule containing curcuminoid and Essential oil of turmeric with 45%Ar-turmerone in a weight ratio of about 1:10 was prepared byencapsulating the above blended extract powder in soft gelatin capsulesdone in an air-conditioned at 21° C. and de-humidified room. 3 kg ofextract powder was charged into the hopper of a semi-automatic capsulefilling machine. ‘0’ size soft gelatin capsule shell was loaded to thetray and the blended extract powder was filled into the shell. Thefilled weights of capsules were checked simultaneously and thesecapsules were sorted by a sorting machine and polished with the help ofa polishing machine.

Example 12

Method of Preparation of Combination of Curcuminoids and Essential Oilof Turmeric with 45% Ar Turmerone in 1:1 Ratio

The powdered curcuminoid mixture prepared as per Example 6 (1.5 Kg) wassuspended in water (6 L) to form a suspension. Fraction of essential oilof turmeric containing 45% Ar-turmerone prepared as per Example 9 (1.5Kg) was added to the suspension in 1:1 ratio. The mixture was pulverizedin a colloidal mill to form fine slurry. Water was stripped from theslurry under heat and vacuum to form a uniform blend. (3 Kg).

A 500 mg capsule containing 250 mg of curcuminoid and 250 mg ofEssential oil of turmeric with 45% Ar-turmerone in a weight ratio ofabout 1:1 was prepared by encapsulating the above blended extract powderin hard gelatin capsules done in an air-conditioned at 21° C. andde-humidified room. 3 kg of extract powder was charged into the hopperof a semi-automatic capsule filling machine. ‘0’ size hard gelatincapsule shell was loaded to the tray and the blended extract powder wasfilled into the shell. The filled weight of capsules were checkedsimultaneously and these capsules were sorted by a sorting machine andpolished with the help of a polishing machine to give 6000 capsules of500 mg each.

Example 13

Method of Preparation of Combination of Curcuminoids and Essential Oilof Turmeric with 10-15% Ar Turmerone in 10:1 Ratio

The powdered curcuminoid mixture prepared as per Example 6 (2.7 Kg) wassuspended in water (12 L) to form a suspension. Fraction of essentialoil of turmeric containing 10-15% Ar-turmerone prepared as per Example 9(0.27 Kg) was added to the suspension in 10:1 ratio. The mixture waspulverized in a colloidal mill to form fine slurry. Water was strippedfrom the slurry under heat and vacuum to form a uniform blend (3 Kg).

A 500 mg capsule containing 454.55 mg of curcuminoid and 45.45 mg ofEssential oil of turmeric with 10-15% Ar-turmerone in a weight ratio ofabout 90:9 (10:1) was prepared by encapsulating the above blendedextract powder in hard gelatin capsules done in an air-conditioned at21° C. and de-humidified room. 3 kg of extract powder was charged intothe hopper of a semi-automatic capsule filling machine. ‘0’ size hardgelatin capsule shell was loaded to the tray and the blended extractpowder was filled into the shell. The filled weight of capsules werechecked simultaneously and these capsules were sorted by a sortingmachine and polished with the help of a polishing machine to give 6000capsules of 500 mg each.

Example 14

Method of Preparation of Capsules Containing Essential Oil of Turmericwith 45% Ar-Turmerone

A 500 mg capsule with essential oil of turmeric containing 45%Ar-turmerone was prepared by encapsulating the essential oil of turmericwith 45% Ar-turmerone prepared as per example 9 (2.5 kg) in soft gelatincapsules done in an air-conditioned at 21° C. and de-humidified room.2.5 kg essential oil of turmeric with 45% Ar-turmerone was charged intothe hopper of a semi-automatic capsule filling machine. ‘0’ size softgelatin capsule shell was loaded to the tray and the blended extractpowder was filled into the shell. The filled weight of capsules werechecked simultaneously and these capsules were sorted by a sortingmachine and polished with the help of a polishing machine to give 5000capsules of 500 mg each.

Example 15

Method of Preparation of Capsules Containing Essential Oil of Turmericwith 10-15% Ar-Turmerone

A 500 mg capsule with essential oil of turmeric containing 10-15%Ar-turmerone was prepared by encapsulating the essential oil with 10-15%Ar-turmerone prepared as per example 9 (2.5 kg) in soft gelatin capsulesdone in an air-conditioned at 21° C. and de-humidified room. 2.5 kgessential oil of turmeric with 10-15% Ar-turmerone was charged into thehopper of a semi-automatic capsule filling machine. ‘0’ size softgelatin capsule shell was loaded to the tray and the blended extractpowder was filled into the shell. The filled weight of capsules werechecked simultaneously and these capsules were sorted by a sortingmachine and polished with the help of a polishing machine to give 5000capsules of 500 mg each.

Example 16

Method of Preparation of Capsules Containing Curcuminoids 95%

A 500 mg capsule containing curcuminoids 95% was prepared byencapsulating the curcuminoid powder with 95% curcuminoids in hardgelatin capsules done in an air-conditioned at 21° C. and de-humidifiedroom. 3 kg of powder was charged into the hopper of a semi-automaticcapsule filling machine. ‘0’ size hard gelatin capsule shell was loadedto the tray and the powder was filled into the shell. The filled weightof capsules were checked simultaneously and these capsules were sortedby a sorting machine and polished with the help of a polishing machineto give 6000 capsules of 500 mg each.

Example 17

Method of Preparation of Combination of Curcuminoids with 24%Curcuminoids and Essential Oil of Turmeric with 45% Ar-Turmerone in 10:1Ratio

The powdered curcuminoid prepared as per Example 7 (2.7 Kg) wassuspended in water (12 L) to form a suspension. Fraction of essentialoil containing 45% Ar-turmerone prepared as per Example 9 (0.27 Kg) wasadded to the suspension in 10:1 ratio. The mixture was pulverized in acolloidal mill to form fine slurry. Water was stripped from the slurryunder heat and vacuum to form a uniform blend (3 Kg).

A 500 mg capsule containing 454.55 mg of curcuminoid and 45.45 mg ofEssential oil with 45% Ar-turmerone in a weight ratio of about 90:9(10:1) was prepared by encapsulating the above blended extract powder inhard gelatin capsules done in an air-conditioned at 21° C. andde-humidified room. 3 kg of extract powder was charged into the hopperof a semi-automatic capsule filling machine. ‘0’ size hard gelatincapsule shell was loaded to the tray and the blended extract powder wasfilled into the shell. The filled weight of capsules were checkedsimultaneously and these capsules were sorted by a sorting machine andpolished with the help of a polishing machine to give 6000 capsules of500 mg each.

Example 18

Method of Preparation of Raw Turmeric Powder

The raw turmeric rhizomes (10 Kg) were collected and cleaned. Therhizomes were dried and pulverized to get turmeric powder (2.5 Kg). Theturmeric powder was sieved through 20 meshes. A 500 mg capsule with rawturmeric powder (curcuminoids 5%) was prepared by encapsulating thepowder in hard gelatin capsules done in an air-conditioned at 21° C. andde-humidified room. 2.5 kg raw turmeric powder is charged into thehopper of a semi-automatic capsule filling machine. ‘0’ size hardgelatin capsule shell was loaded to the tray and the blended extractpowder was filled into the shell. The filled weight of capsules werechecked simultaneously and these capsules were sorted by a sortingmachine and polished with the help of a polishing machine to give 5000capsules of 500 mg each.

Example 19

Method of Preparation of Combination of Curcuminoids and Essential Oilof Turmeric with 45% Ar Turmerone in 12:1 Ratio

The curcuminoid powder prepared as per Example 6 (3.5 Kg) was suspendedin water (15 L) to form a suspension. Fraction of essential oilcontaining 45% Ar-turmerone prepared as per Example 9 (0.29 Kg) wasadded to the suspension in 12:1 ratio. The mixture is pulverized in acolloidal mill to form fine slurry. Water is stripped from the slurryunder heat and vacuum to form a uniform blend. (3.8 Kg).

A 500 mg capsule containing 461.5 mg of curcuminoid and 38.45 mg ofEssential oil with 45% Ar-turmerone in a weight ratio of about 12:1(curcumin 69.5%, demethoxy curcumin 17% and bisdemethoxy curcumin 4% andEssential oil of turmeric 7.5%) was prepared by encapsulating the aboveblended extract powder in hard gelatin capsules done in anair-conditioned at 21° C. and de-humidified room. 3 kg of extract powderwas charged into the hopper of a semi-automatic capsule filling machine.‘0’ size hard gelatin capsule shell was loaded to the tray and theblended extract powder was filled into the shell. The filled weight ofcapsules were checked simultaneously and these capsules were sorted by asorting machine and polished with the help of a polishing machine togive 6000 capsules of 500 mg each.

Example 20

Human Clinical Study of Different Turmeric Extracts in Patients withRheumatoid Arthritis

In a human clinical study to assess the efficacy of formulation ofcurcuminoid with essential oil of turmeric with 45% Ar-turmerone in 10:1ratio compared to raw turmeric powder, essential oil of turmeric with45% Ar-turmerone, essential oil of turmeric with 10-15% Ar-turmerone,curcuminoid with essential oil of turmeric with 45% Ar-turmerone in 1:10ratio, curcuminoid with essential oil of turmeric with 45% Ar-turmeronein 1:1 ratio, curcuminoid 24% with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio, curcuminoid with essential oil of turmericwith 10-15% Ar-turmerone in 10:1 ratio, Curcuminoid with essential oilof turmeric with 45% Ar-turmerone in 12:1 ratio, and curcuminoids 95% inpatients with rheumatoid arthritis, 50 patients diagnosed withrheumatoid arthritis were randomized into 10 groups viz.,

Group1: Subjects receiving raw turmeric powder 500 mg capsules preparedas described in Example 18 twice daily

Group2: Subjects receiving essential oil of turmeric with 45%Ar-turmerone (EOT with 45% Ar-t) 500 mg capsules prepared as describedin Example 14 twice daily

Group3: Subjects receiving essential oil of turmeric with 10-15%Ar-turmerone (EOT with 10-15% Ar-t) 500 mg capsules prepared asdescribed in Example 15 twice daily

Group4: Subjects receiving curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 1:10 ratio (C+E with 45% Ar-t in 1:10 ratio),500 mg capsules prepared as described in Example 11 twice daily.

Group5: Subjects receiving curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 1:1 ratio (C+E with 45% Ar-t in 1:1 ratio), 500mg capsules prepared as described in Example 12 twice daily

Group6: Subjects receiving curcuminoid 24% with essential oil ofturmeric with 45% Ar-turmerone in 10:1 ratio (C 24%+E with 45% Ar-t in10:1 ratio), 500 mg capsules prepared as described in Example 17 twicedaily.

Group7: Subjects receiving curcuminoid with essential oil of turmericwith 10-15% Ar-turmerone in 10:1 ratio (C+E with 10-15% Ar-t in 10:1ratio), 500 mg capsules prepared as described in Example 13 twice daily

Group8: Subjects receiving curcuminoids 95% 500 mg capsules prepared asdescribed in Example 16, twice daily.

Group9: Subjects receiving formulation of curcuminoid with essential oilof turmeric with 45% Ar-turmerone in 10:1 ratio (C+E with 45% Ar-t in10:1 ratio) 500 mg capsules prepared as described in Example 10, twicedaily dose after food with water for a period of 8 weeks.Group10: Subjects receiving formulation of curcuminoid with essentialoil of turmeric with 45% Ar-turmerone in 12:1 ratio (C+E with 45% Ar-tin 12:1 ratio) 500 mg capsules prepared as described in Example 19,twice daily dose after food with water for a period of 8 weeks.

Subjects aged 18-65 years of either sex diagnosed to have rheumatoidarthritis (RA) according to the revised 1987 ACR criteria for theclassification of rheumatoid arthritis Class I or II, with DiseaseActivity Score (DAS)>5, receiving treatment on an outpatient basis wereincluded in the study. Patients with inflammatory joint disease otherthan RA and having concurrent treatment with any NSAID, DMARD or anyanti-TNF-α therapy or other anti arthritic therapy were excluded. Thestudy examinations included general and clinical examination, evaluationof disease, recording of vital signs, X-ray AP view ofchest/hands/wrist/foot, ECG, Haematology, Blood chemistry and UrinePregnancy Test for women of child bearing potential.

Efficacy and safety evaluations were performed at biweekly intervals.Patients were assessed for the primary efficacy endpoints diseaseactivity score (DAS) 28 and ACR criteria. DAS is the numerical sum offour outcome parameters: tender and swollen joint count (28-jointassessment), patient's global assessment of disease on a visual analogscale (VAS; 0, no pain and 100, severe pain); and erythrocytesedimentation rate. The ACR criteria are indicated as ACR 20, ACR 50,and ACR 70. ACR criteria measures improvement in tender or swollen jointcounts and improvement in three of the following five parameters:patient global assessment—global assessment of disease activity on a0-100 scale (0, best; 100, worst); physician assessment—globalassessment of disease activity on a 0-100 scale (0, best; 100, worst);pain scale disability—visual analogue scale for pain (VAS; 0, no painand 100, severe pain); functional questionnaire—HAQ (Health AssessmentQuestionnaire) includes four categories: dressing and grooming, arising,eating, and walking, on a 0-3 scale (0, best: 3, worst); acute phasereactant (such as sedimentation rate). ACR20 is defined as a reductionin tender and swollen joint counts of 20%, ACR 50 of 50% and ACR 70 of70%, from baseline. Monitoring of vital signs, physical examinations,laboratory parameters (hematology, blood chemistry, C-reactive protein(CRP), antistreptolysin-O (ASO), rheumatoid factor and blood sugar) wereperformed biweekly for safety evaluation. The occurrence of adverseevents was the primary safety variable.

Treatment with formulation of curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 12:1 ratio showed decrease in disease activityscore from 6.5 at baseline to 3 at the end of treatment.

Treatment with formulation of curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 10:1 ratio showed decrease in disease activityscore from 6.5 at baseline to 3.5 at the end of treatment. The resultsare summarized in Table 7. Mean VAS scores for pain in all the groupswere comparable at baseline, and formulation of curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 10:1 ratio groupshowed significant reduction (65%) in VAS score from 79 mm at baselineto 27.5 mm at the end of treatment. Mean VAS scores for pain in thegroup with formulation of curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 12:1 ratio group also showed significantreduction (69%) in VAS score from 78 mm at baseline to 24 mm at the endof treatment. The results are summarized in Table 8. All components ofACR response criteria viz., Total Painful Joints, Total Swollen Joints.Patient's GA, Physician's GA, Disability Index and HAQ showed asignificant reduction from baseline to end of study in the formulationof curcuminoid with essential oil of turmeric with 45% Ar-turmerone in12:1 and 10:1 ratios. The results are summarized in Table 9 (FIG. 6).Treatment with formulation of curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 12:1 ratio group showed decreased C reactiveprotein from 12 mg/L at baseline to 5.3 mg/L at the end of treatment andformulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio showed decreased C reactive protein from 12mg/L at baseline to 5.7 mg/L at the end of treatment. The results aresummarized in Table 10. Treatment with formulation of curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 12:1 ratio groupshowed decrease in Rheumatoid Arthritis factor from 23 IU/L at baselineto 13 IU/L at the end of treatment. Formulation of curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 10:1 ratio showeddecrease in Rheumatoid Arthritis factor from 24 IU/L at baseline to 15IU/L at the end of treatment. The results are summarized in Table 11.The study shows that formulation of curcuminoid with essential oil ofturmeric with 45% Ar-turmerone in 10:1 and 12:1 ratios can providesignificant improvement in treatment efficacy in active RA. All thepatients who were given raw turmeric powder, essential oil of turmericwith 45% Ar-turmerone, essential oil of turmeric with 10-15%Ar-turmerone, curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 1:10 ratio, curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 1:1 ratio, curcuminoid 24% with essential oilof turmeric with 45% Ar-turmerone in 10:1 ratio, curcuminoid withessential oil of turmeric with 10-15% Ar-turmerone in 10:1 ratio orcurcuminoids 95% capsules showed no significant improvement withtreatment and some of the patients even showed worsening of theirsymptoms with time even with treatment.

TABLE 7 Treatment efficacy results—Disease Activity Score End of % GroupBaseline Treatment Change Raw turmeric Mean 6 6.5 8% EOT with 45% Mean6.5 6.5 0 Ar-t EOT with 10- Mean 6.5 7 7% 15% Ar-t C + E with Mean 7 7.56.6%   45% Ar-t in 1:10 ratio C + E with Mean 7.5 7.5 0 45% Ar-t in 1:1ratio C 24% + E Mean 7 7 0 with 45% Ar-t in 10:1 ratio C + E with 10-Mean 6 6 0 15% Ar-t in 10:1 ratio C + E with Mean 6.5 3.5 46%  45% Ar-tin 10:1 ratio Curcuminoids Mean 6.5 6 8% 95% C + E with Mean 6.5 3 54% 45% Ar-t in 12:1 ratio

TABLE 8 Treatment efficacy results—VAS End of Baseline Treatment % Group(mm) (mm) Change Raw turmeric Mean 80 78 2.5% EOT with 45% Ar-t Mean 7577 2.6% EOT with 10-15% Ar-t Mean 77 78 1.3% C + E with 45% Ar-t Mean 7977 2.5% in 1:10 ratio C + E with 45% Ar-t Mean 78 76 2.6% in 1:1 ratio C24% + E with 45% Mean 76 74 2.6% Ar-t in 10:1 ratio C + E with 10-15%Mean 75 71 5.3% Ar-t in 10:1 ratio C + E with 45% Ar-t Mean 79 27.5  65%in 10:1 nitio Curcuminoids 95% Mean 77 70   9% C + E with 45% Ar-t Mean78 24  69% in 12:1 ratio

TABLE 10 Treatment efficacy results—CRP End of Baseline Treatment %Group (mg/L) (mg/L) Change Raw turmeric Mean 13 13 0    EOT with Mean 1111.5 4% 45% Ar-t EOT with 10- Mean 12.5 13.5 7% 15% Ar-t C + E with 45%Mean 12 12.5 4% Ar-t in 1:10 ratio C + E with 45% Mean 13 13 0 Ar-t in1:1 ratio C 24% + E Mean 12 12 0 with 45% Ar-t in 10:1 ratio C + E with10- Mean 11.5 11.5 0 15% Ar-t in 10:1 ratio C + E with 45% Mean 12 5.753%  Ar-t in 10:1 ratio Curcuminoids Mean 11.5 11.4 1% 95% C + E with45% Mean 12 5.3 56%  Ar-t in 12:1 ratio

TABLE 11 Treatment efficacy results—Rheumatoid Arthritis Factor End ofBaseline Treatment % Group (IU/L) (IU/L) Change Raw turmeric Mean 23 258% EOT with 45% Mean 26 28 7% Ar-t EOT with 10-15% Mean 25 26 3.8%  Ar-t C + E with 45% Mean 23 24 4% Ar-t in 1:10 ratio C + E with 45% Mean22 22 0    Ar-t in 1:1 ratio C 24% + E with Mean 21 21 0    45% Ar-t in10:1 ratio C + E with 10- Mean 24 24 0    15% Ar-t in 10:1 ratio C + Ewith 45% Mean 24 15 38%  Ar-t in 10:1 ratio Curcuminoids Mean 22 24 9%95% C + E with 45% Mean 22 13 39%  Ar-t in 12:1 ratio

Example 21

Human Clinical Study of Different Turmeric Extracts in Patients withOsteo Arthritis

In a human clinical trial to determine the effectiveness of formulationof curcuminoid with essential oil of turmeric with 45% Ar-turmerone in10:1 ratio in relieving symptoms and clinical conditions ofosteoarthritic patients compared with raw turmeric powder, essential oilof turmeric with 45% Ar-turmerone, essential oil of turmeric with 10-15%Ar-turmerone, curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 1:10 ratio, curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 1:1 ratio, curcuminoid 24% with essential oilof turmeric with 45% Ar-turmerone in 10:1 ratio, curcuminoid withessential oil of turmeric with 10-15% Ar-turmerone in 10:1 ratio,formulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 12:1 ratio and curcuminoids 95% capsules, patients ofeither sex diagnosed to have osteoarthritis according to ACR criteriawere selected for the study. The patients were divided into nine groupsof 5 patients each.

Gr 1: Oral administration of raw turmeric powder 500 mg capsules,prepared as described in Example 18, in twice daily dosage

Gr 2: Oral administration of essential oil of turmeric with 45%Ar-turmerone (EOT with 45% Ar-t) 500 mg capsules prepared as describedin Example 14, in twice daily dosage.

Gr3: Oral administration of essential oil of turmeric with 10-15%Ar-turmerone (EOT with 10-15% Ar-t) 500 mg capsules prepared asdescribed in Example 15, in twice daily dosage.

Gr4: Oral administration of curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 1:10 ratio (C+E with 45% Ar-t in 1:10 ratio),500 mg capsules prepared as described in Example 11, in twice dailydosage.

Gr5: Oral administration of curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 1:1 ratio (C+E with 45% Ar-t in 1:1 ratio), 500mg capsules prepared as described in Example 12, in twice daily dosage.

Gr6: Subjects receiving curcuminoid 24% with essential oil of turmericwith 45% Ar-turmerone in 10:1 ratio (C 24%+E with 45% Ar-t in 10:1ratio), 500 mg capsules prepared as described in Example 17 twice daily

Gr7: Oral administration of curcuminoid with essential oil of turmericwith 10-15% Ar-turmerone in 10:1 ratio (C+E with 10-15% Ar-t in 10:1ratio), 500 mg capsules prepared as described in Example 13, in twicedaily dosage.

Gr8: Oral administration of formulation of curcuminoid with essentialoil of turmeric with 45% Ar-turmerone in 10:1 ratio (C+E with 45% Ar-tin 10:1 ratio), 500 mg capsule prepared as described in Example 10, intwice daily dosage

Gr 9: Oral administration of curcuminoids 95% 500 mg capsule prepared asdescribed in Example 16, in twice daily dosage.

Gr10: Oral administration of formulation of curcuminoid with essentialoil of turmeric with 45% Ar-turmerone in 12:1 ratio (C+E with 45% Ar-tin 12:1 ratio), 500 mg capsule prepared as described in Example 19, intwice daily dosage

Each patient was given treatment for 12 weeks. The efficacy of the useof the study drugs over the treatment period was evaluated by symptomscoring and clinical examination. Symptom refers to the complaintsexpressed by the patient and scored depending on severity. Symptomscoring includes joint pain measurements and walking distancemeasurements. Joint pain in osteoarthritis is a deep pain localized tothe joint and is measured by querying the patient and scoring it asNo/mild/moderate/severe during each visit. Results of this analysis forthe eight treatment groups are presented in Table 12 (FIG. 7). Walkingdistance refers to the maximum distance a person is able to walk at astretch without limiting pain. Walking distance measurements wererecorded and are given Table 13 (FIG. 8). Joint line tenderness waselicited by palpating along the joint line and was measured by queryingthe patient and recording the response as No/mild/moderate/severe andwas recorded and results are presented in Table 14 (FIG. 9).

Crepitus (crackling or grating feeling or sound in joints) is elicitedby palpating the joint on movement and scoring it asNo/Mild/Moderate/Severe. Range of movement of the knee is measured forflexion/extension movement and the normal range is from 0 to 135 degrees(0 being neutral position and increasing flexion of the joint isnormally up to 135 degrees). It is measured using a Goniometer and ismeasured by asking the patient to flex the joint to the maximum extentpossible and the maximum value was recorded.

The results showed that the % response of patients taking formulation ofcurcuminoid with essential oil of turmeric with 45% Ar-turmerone in 10:1and 12:1 ratios were significantly better than patients taking rawturmeric powder, essential oil of turmeric with 45% Ar-turmerone,essential oil of turmeric with 10-15% Ar-turmerone, curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 1:10 ratio,curcuminoid with essential oil of turmeric with 45% Ar-turmerone in 1:1ratio, curcuminoid 24% with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio, curcuminoid with essential oil of turmericwith 10-15% Ar-turmerone in 10:1 ratio and curcuminoids 95% capsules. Atthe beginning of study all patients had joint pain and after treatmentwith formulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 12:1 ratio, 19% patients did not have any joint pain.The percentage of patients with moderate joint pain decreased from 80%at baseline to 29% at the end of treatment and majority of the patients(52%) had only mild pain at the end of 3 months of treatment in patientsgiven formulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 12:1 ratio. Before the treatment 7% of patients hadsevere joint pain and after treatment none of the patients givenformulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 12:1 ratio had severe joint pain.

At the beginning of study all patients had joint pain and aftertreatment with formulation of curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 10:1 ratio, 17% patients did not have any jointpain. The percentage of patients with moderate joint pain decreased from78% at baseline to 30% at the end of treatment and majority of thepatients (53%) had only mild pain at the end of 3 months of treatment inpatients given formulation of curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 10:1 ratio. Before the treatment 7% of patientshad severe joint pain and after treatment none of the patients givenformulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio had severe joint pain.

Before the treatment 87% of patients given formulation of curcuminoidwith essential oil of turmeric with 45% Ar-turmerone in 12:1 ratio hadjoint line tenderness and after treatment 52% of patients no longer hadpain and the remaining 48% patients showed improvement and none of thepatient's condition worsened or remained same without change.

Before the treatment 86% of patients given formulation of curcuminoidwith essential oil of turmeric with 45% Ar-turmerone in 10:1 ratio hadjoint line tenderness and after treatment 50% of patients no longer hadpain and the remaining 50% patients showed improvement and none of thepatient's condition worsened or remained same without change.

Before the treatment with formulation of curcuminoid with essential oilof turmeric with 45% Ar-turmerone in 12:1 ratio 8% of patients could notwalk even up to 100 meters. And after the treatment 75% of patientscould walk over 1000 meters and 22% could walk 500-1000 meters.

Before the treatment with formulation of curcuminoid with essential oilof turmeric with 45% Ar-turmerone in 10:1 ratio 7% of patients could notwalk even up to 100 meters. And after the treatment 72% of patientscould walk over 1000 meters and the remaining 28% could walk 500-1000meters.

The safety of the test drug was evaluated by measuring vital signs(systolic and diastolic blood pressure, pulse rate, respiratory rate),haemogram measurement (Hb, TC, DC, ESR), liver function tests (SGOT,SGPT, SAP, bilirubin), renal function tests (blood urea, serumcreatinine). None of these parameters were adversely modified by thestudy drugs. There were also no adverse events reported in the study.

In conclusion, formulation of curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 10:1 and 12:1 ratios were significantlyeffective compared to raw turmeric powder, essential oil of turmericwith 45% Ar-turmerone, essential oil of turmeric with 10-15%Ar-turmerone, curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 1:10 ratio, curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 1:1 ratio, curcuminoid 24% with essential oilof turmeric with 45% Ar-turmerone in 10:1 ratio, curcuminoid withessential oil of turmeric with 10-15% Ar-turmerone in 10:1 ratio andcurcuminoids 95% capsules in relieving symptoms and clinical conditionsof osteoarthritic patients when given over a period of 3 months. Therewas significant improvement in pain scores, walking distance, joint linetenderness, crepitus, range of movement of the knee and joint swellingmeasurements in osteoarthritic patients receiving formulation ofcurcuminoid with essential oil of turmeric with 45% Ar-turmerone in 10:1and 12:1 ratios for 3 months compared to patients receiving raw turmericpowder, essential oil of turmeric with 45% Ar-turmerone, essential oilof turmeric with 10-15% Ar-turmerone, curcuminoid with essential oil ofturmeric with 45% Ar-turmerone in 1:10 ratio, curcuminoid with essentialoil of turmeric with 45% Ar-turmerone in 1:1 ratio, curcuminoid 24% withessential oil of turmeric with 45% Ar-turmerone in 10:1 ratio,curcuminoid with essential oil of turmeric with 10-15% Ar-turmerone in10:1 ratio and curcuminoids 95% capsules in the similar dosage. Thestudy drugs were well tolerated and no dose-related toxicity was found.

Example 22

Human Clinical Study in Patients with Alzheimers Disease

A double-blind, placebo-controlled, pilot clinical trial formulation ofcurcuminoid with essential oil of turmeric with 45% Ar-turmerone in 10:1and 12:1 ratio capsules compared with raw turmeric powder, essential oilof turmeric with 45% Ar-turmerone, essential oil of turmeric with 10-15%Ar-turmerone, curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 1:10 ratio, curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 1:1 ratio, curcuminoid 24% with essential oilof turmeric with 45% Ar-turmerone in 10:1 ratio, curcuminoid withessential oil of turmeric with 10-15% Ar-turmerone in 10:1 ratio andcurcuminoids 95% capsules was done in patients with progressive declinein memory or cognitive function and diagnosed with probable or possibleAlzheimer's disease (AD). Patients were randomized to 10 groups toreceive 3.0 grams of each study drug capsules twice daily for 12 months.

Parameters measured at baseline and end of study include plasmaisoprostanes, Vit E, Aβ and clinical assessment with Mini-Mental StateExamination Scores (MMSE). Isoprostanes are the products ofnon-enzymatic oxidation of arachidonic acid and so this, along with theantioxidant Vit E levels is indicative of the level of oxidative stress.Aβ are a 39-43 amino acid peptide fragment derived from the β-amyloidprecursor protein (APP) and are the predominant component of theneuritic plaques, an invariant pathological hallmark of AD. Aggregatedforms of Aβ are believed to be the real culprits of the disease.Mini-Mental State Examination Scores (MMSE) is a measure of cognitivefunction. The pharmacokinetics of curcumin from the ingested drugs andadverse events, if any, associated with the drug were also recorded.

Serum Aβ levels was significantly higher in formulation of curcuminoidwith essential oil of turmeric with 45% Ar-turmerone in 10:1 and 12:1ratio capsules compared to results following administration of rawturmeric powder, essential oil of turmeric with 45% Ar-turmerone,essential oil of turmeric with 10-15% Ar-turmerone, curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 1:10 ratio,curcuminoid with essential oil of turmeric with 45% Ar-turmerone in 1:1ratio, curcuminoid 24% with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio, curcuminoid with essential oil of turmericwith 10-15% Ar-turmerone in 10:1 ratio and curcuminoids 95% capsules,reflecting the increased ability of formulation of curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 10:1 and 12:1 ratiocapsules to disaggregate AΔ deposits in the brain. The MMSE scores ofpatients given formulation of curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 10:1 ratio capsules increased significantlyfrom baseline value at 16/30 to 23/30 at the end of the study. The MMSEscores of patients given formulation of curcuminoid with essential oilof turmeric with 45% Ar-turmerone in 12:1 ratio capsules increasedsignificantly from baseline value at 17/30 to 25/30 at the end of thestudy and in patients given raw turmeric powder, essential oil ofturmeric with 45% Ar-turmerone, essential oil of turmeric with 10-15%Ar-turmerone, curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 1:10 ratio, curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 1:1 ratio, curcuminoid 24% with essential oilof turmeric with 45% Ar-turmerone in 10:1 ratio, curcuminoid withessential oil of turmeric with 10-15% Ar-turmerone in 10:1 ratio andcurcuminoids 95% capsules there was a marginal deterioration in the MMSEscore (Table 15). Isoprostanes are products of non-enzymatic oxidationof arachidonic acid and are indicative of oxidative stress. Plasmaisoprostane levels were significantly lowered between baseline and at 12months in patients taking formulation of curcuminoid with essential oilof turmeric with 45% Ar-turmerone in 10:1 and 12:1 ratios. Vitamin Elevels increased in the formulation of curcuminoid with essential oil ofturmeric with 45% Ar-turmerone in 10:1 and 12:1 ratio groups frombaseline to end of treatment. (Table 16). The curcumin level in patientstaking formulation of curcuminoid with essential oil of turmeric with45% Ar-turmerone in 10:1 ratio (baseline at 12 to 653 at the end oftreatment period) was 15 times higher than patients taking curcuminoids95% capsules (baseline at 13 to 42 at the end of treatment) (Table 17).The curcumin level in patients taking formulation of curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 12:1 ratio (baselineat 14 to 875 at the end of treatment period) was 20 times higher thanpatients taking curcuminoids 95% capsules (baseline at 13 to 42 at theend of treatment) (Table 17). In patients taking raw turmeric powder,essential oil of turmeric with 45% Ar-turmerone, essential oil ofturmeric with 10-15% Ar-turmerone, curcuminoid with essential oil ofturmeric with 45% Ar-turmerone in 1:10 ratio, curcuminoid with essentialoil of turmeric with 45% Ar-turmerone in 1:1 ratio, curcuminoid 24% withessential oil of turmeric with 45% Ar-turmerone in 10:1 ratio,curcuminoid with essential oil of turmeric with 10-15% Ar-turmerone in10:1 ratio and curcuminoids 95% capsules there was no decrease noticedin the plasma isoprostane levels and Vitamin E levels remained more orless the same in all the groups except in patients taking formulation ofcurcuminoid with essential oil of turmeric with 45% Ar-turmerone in 10:1and 12:1 ratios.

This study thus reveals that the formulation of curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 10:1 and 12:1 ratiocapsules confer greater clinical benefits as observed by significantincrease in the MMSE score, increase in Vit E levels, high levels ofserum Aβ levels, and lowered plasma isoprostane levels in patientsconsuming formulation of curcuminoid with essential oil of turmeric with45% Ar-turmerone in 10:1 and 12:1 ratio capsules compared with patientsconsuming raw turmeric powder, essential oil of turmeric with 45%Ar-turmerone, essential oil of turmeric with 10-15% Ar-turmerone,curcuminoid with essential oil of turmeric with 45% Ar-turmerone in 1:10ratio, curcuminoid with essential oil of turmeric with 45% Ar-turmeronein 1:1 ratio, curcuminoid 24% with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio, curcuminoid with essential oil of turmericwith 10-15% Ar-turmerone in 10:1 ratio and curcuminoid 95% capsules for12 months.

TABLE 15 MMSE levels of patients in each group over 12 months BaselineStudy End Groups 0 month 12 months Raw turmeric MMSE 16/30 14/30 EOTwith 45% Ar-t MMSE 15/30 14/30 EOT with 10-15% MMSE 18/30 16/30 Ar-t C +E with 45% Ar-t MMSE 16/30 15/30 in 1:10 ratio C + E with 45% Ar-t MMSE18/30 17/30 in 1:1 ratio C 24% + E with MMSE 16/30 16/30 45% Ar-t in10:1 ratio C + E with 10-15% MMSE 17/30 17/30 Ar-t in 10:1 ratio C + Ewith 45% Ar-t MMSE 16/30 23/30 in 10:1 ratio Curcuminoids 95% MMSE 17/3016/30 C + E with 45% Ar-t MMSE 17/30 25/30 in 12:1 ratio

TABLE 16 Vitamin E levels of patients in each group over 12 monthsBaseline Study End Groups 0 month 12 months Raw turmeric Vit E in 0.40.4 mg % EOT with Vit. E in 0.3 0.3 45% Ar-t mg % EOT with 10- Vit E in0.3 0.3 15% Ar-t mg % C + E with 45% Vit. E in 0.4 0.4 Ar-t in 1:10ratio mg % C + E with 45% Vit. E in 0.3 0.3 Ar-t in 1:1 ratio mg % C24% + E with Vit E in 0.4 0.4 45% Ar-t in 10:1 mg % ratio C + E with 10-Vit E in 0.3 0.4 15% Ar-t in 10:1 mg % ratio C + E with 45% Vit E in0.30 2.1 Ar-t in 10:1 ratio mg % Curcuminoids Vit E in 0.4 0.4 95% mg %C + E with 45% Vit E in 0.3 2.8 Ar-t in 12:1 ratio mg %

TABLE 17 Plasma level of curcumin in patients in each group over 12months Baseline Study End Groups 0 month 12 months Raw tumeric Curcuminin 11 20 nMol/L EOT with Curcumin in 9 11 45% Ar-t nMol/L EOT with 10-Curcumin in 12 11 15% Ar-t nMol/L C + E with 45% Curcumin in 10 13 Ar-tin 1:10 ratio nMol/L C + E with 45% Curcumin in 21 145 Ar-t in 1:1 rationMol/L C 24% + E with Curcumin in 14 28 45% Ar-t in 10:1 nMol/L ratioC + E with 10- Curcumin in 15 82 15% Ar-t in 10:1 nMol/L ratio C + Ewith 45% Curcumin in 12 653 Ar-t in 10:1 ratio nMol/L CurcuminoidsCurcumin in 13 42 95% nMol/L C + E with 45% Curcumin in 14 875 Ar-t in12:1 ratio nMol/L

Example 23

Human Clinical Study of Patients with Depression

In a randomized, double blind, active control, parallel group study,formulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 10:1 and 12:1 ratios were studied against raw turmericpowder, essential oil of turmeric with 45% Ar-turmerone, essential oilof turmeric with 10-15% Ar-turmerone, curcuminoid with essential oil ofturmeric with 45% Ar-turmerone in 1:10 ratio, curcuminoid with essentialoil of turmeric with 45% Ar-turmerone in 1:1 ratio, curcuminoid 24% withessential oil of turmeric with 45% Ar-turmerone in 10:1 ratio,curcuminoid with essential oil of turmeric with 10-15% Ar-turmerone in10:1 ratio and curcuminoid 95% capsules in patients with depression tocompare the efficacy and tolerability of the eight formulations.Patients with a Score greater than 7 but less than 24 on the 17-itemHamilton Depression (HAM-D) Scale and assessed by Structured ClinicalInterview or DSM-IV Axis 1 Disorders without any concurrent treatmentwere selected for the study. 50 patients selected were randomized into10 groups and were given treatment for 8 weeks.

Gr 1: raw turmeric powder 500 mg capsules prepared as described inExample 18 twice daily

Gr 2: essential oil of turmeric with 45% Ar-turmerone (EOT with 45%Ar-t) 500 mg capsules prepared as described in Example 14 twice daily.

Gr3: essential oil of turmeric with 10-15% Ar-turmerone (EOT with 10-15%Ar-t) 500 mg capsules prepared as described in Example 15 twice daily

Gr4: curcuminoid with essential oil of turmeric with 45% Ar-turmerone in1:10 ratio (C+E with 45% Ar-t in 1:10 ratio), 500 mg capsules preparedas described in Example 11 twice daily

Gr5: curcuminoid with essential oil of turmeric with 45% Ar-turmerone in1:1 ratio (C+E with 45% Ar-t in 1:1 ratio), 500 mg capsules prepared asdescribed in Example 12 twice daily.

Gr6: Subjects receiving curcuminoid 24% with essential oil of turmericwith 45% Ar-turmerone in 10:1 ratio (C 24%+E with 45% Ar-t in 10:1ratio), 500 mg capsules prepared as described in Example 17 twice daily.

Gr7: curcuminoid with essential oil of turmeric with 10-15% Ar-turmeronein 10:1 ratio (C+E with 10-15% Ar-t in 10:1 ratio), 500 mg capsulesprepared as described in Example 13 twice daily.

Gr 8: curcuminoids 95% (500 mg) capsules prepared as described inexample 16 twice daily.

Gr 9: Formulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio (C+E with 45% Ar-t in 10:1 ratio) (500 mg)capsules prepared as described in Example 10 twice daily.

Gr 10: Formulation of curcuminoid with essential oil of turmeric with45% Ar-turmerone in 12:1 ratio (C+E with 45% Ar-t in 12:1 ratio) (500mg) capsules prepared as described in Example 19 twice daily.

Efficacy was evaluated by using 17 point—Hamilton depression scale andclinical global impression by Global Severity (CGI-S) and Global change(CGI-I) scales. Tolerability of the drugs was assessed clinically and bybiochemical parameters like SGOT, SGPT, Urea and Creatinine (measured atthe start and at the end of study).

Results: The proportion of responders as measured by the HAM-D17 scalewas significantly (97%) higher in the formulation of curcuminoid withessential oil of turmeric with 45% Ar-turmerone in 12:1 ratio group thanother groups (Table: 18). The proportion of responders as measured bythe RAM-D17 scale was significantly (93%) higher in the formulation ofcurcuminoid with essential oil of turmeric with 45% Ar-turmerone in 10:1ratio group than other groups (Table: 18). The change in HAM-D17 scoresat the end of 8 weeks from baseline at 20 to 7 at the end of treatmentwas higher for formulation of curcuminoid with essential oil of turmericwith 45% Ar-turmerone in 12:1 ratio group (65%) than other groups(Table: 19). The change in HAM-D17 scores at the end of 8 weeks frombaseline at 21 to 10 at the end of treatment was also higher forformulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 10:1 ratio group (52%) than other groups (Table: 19). InClinical Global Impression assessment scale, the formulation ofcurcuminoid with essential oil of turmeric with 45% Ar-turmerone in 12:1ratio group showed a decrease in CGI-S score from baseline at 4 to 1 atthe end of treatment. That is 75% improvement in CGI-S (Table; 20). InClinical Global Impression assessment scale, the formulation ofcurcuminoid with essential oil of turmeric with 45% Ar-turmerone in 10:1ratio group showed a decrease in CGI-S score from baseline at 5 to 2 atthe end of treatment. That is 60% improvement in CGI-S (Table: 20).Formulation of curcuminoid with essential oil of turmeric with 45%Ar-turmerone in 12:1 ratio group showed a decrease in CGI-I score frombaseline 5 to 2 at the end of treatment. That is 60% improvement inCGI-1 scale (Table: 21). Formulation of curcuminoid with essential oilof turmeric with 45% Ar-turmerone in 10:1 ratio group showed a decreasein CGI-1 score from baseline 4 to 2 at the end of treatment. That is 50%improvement in CGI-1 scale (Table: 21). Whereas the other groups showedno change at all at the end of 8 weeks of treatment. Overall the studymedications were well tolerated and there was no significant differencein vital signs, physical examination, laboratory tests andelectrocardiogram from baseline and had ‘excellent’ tolerability.

TABLE 18 Proportion of responders in each group over 2 months Rawturmeric % response rate on  6% HAM-D17 scale EOT with 45% Ar-t %response rate on  4% HAM-D17 scale EOT with 10-15% Ar-t % response rateon  4% HAM-D17 scale C + E with 45% Ar-t in %, response rate on  7% 1:10ratio HAM-D17 scale C + E with 45% Ar-t in % response rate on  9% 1:1ratio HAM-D17 scale C 24% + E with 45% % response rate on  8% Ar-t in10:1 ratio HAM-D17 scale C + E with 10-15% Ar-t % response rate on 12%in 10:1 ratio HAM-D17 scale C + E with 45% Ar-t in % response rate on93% 10:1 ratio HAM-D17 scale Curcuminoids 95% % response rate on 10%HAM-D17 scale C + E with 45% Ar-t in % response rate on 97% 12:1 ratioHAM-D17 scale

TABLE 19 Hamilton Depression Scoring Scale—17 point scale in patients ineach group over 2 months Baseline Study End Groups 0 month 2 months Rawturmeric HAM-D17 20 19 scale EOT with 45% HAM-D17 19 19 Ar-t scale EOTwith 10-15% HAM-D17 22 22 Ar-t scale C + E with 45% HAM-D17 18 18 Ar-tin 1:10 ratio scale C + E with 45% HAM-D17 20 19 Ar-t in 1:1 ratio scaleC 24% + E with HAM-D17 19 19 45% Ar-t in 1:10 scale ratio C + E with10-15% HAM-D17 19 16 Ar-t in 10:1 ratio scale C + E with 45% HAM-D17 2110 Ar-t in 10:1 ratio scale Curcuminoids 95% HAM-D17 19 17 scale C + Ewith 45% HAM-D17 20 7 Ar-t in 12:1 ratio scale

TABLE 20 Clinical Global Impression—Severity Scale in patients in eachgroup over 2 months Baseline Study End Groups 0 month 12 months Rawturmeric CGI-S score 5 5 EOT with 45% Ar-t CGI-S score 4 4 EOT with10-15% Ar-t CGI-S score 4 4 C + E with 45% Ar-t in CGI-S score 5 5 1:10ratio C + E with 45% Ar-t in CGI-S score 4 4 1:1 ratio C 24% + E with45% CGI-S score 4 4 Ar-t in 10:1 ratio C + E with 10-15% CGI-S score 5 5Ar-t in 10:1 ratio C + E with 45% Ar-t in CGI-S score 5 2 10:1 ratioCurcuminoids 95% CGI-S score 5 5 C + E with 45% Ar-t in CGI-S score 4 112:1 ratio

TABLE 21 Clinical Global Impression—Improvement/Change Scale in patientsin each group over 2 months Baseline Study End Groups 0 month 12 monthsRaw turmeric CGI-I score 4 4 EOT with 45% Ar-t CGI-I score 4 4 EOT with10-15% Ar-t CGI-I score 4 4 C + E with 45% Ar-t CGI-I score 5 5 in 1:10ratio C + E with 45% Ar-t in CGI-I score 4 4 1:1 ratio C 24% + E with45% CGI-I score 4 4 Ar-t in 10:1 ratio C + E with 10-15% Ar-t CGI-Iscore 5 5 in 10:1 ratio C + E with 45% Ar-t in CGI-I score 4 2 10:1ratio Curcuminoids 95% CGI-I score 4 4 C + E with 45% Ar-t CGI-I score 52 12:1 ratio

Other modifications and variations to the invention will be apparent tothose skilled in the art from the foregoing disclosure and teachings.Thus, while only certain embodiments of the invention have beenspecifically described herein, it will be apparent that numerousmodifications may be made thereto without departing from the spirit andscope of the invention.

REFERENCES

-   1. Kelloff, G. I., et al, J. Cell Biochem., 1996, 265:54-71.-   2. Rao, C. V. et al, Cancer Res., 1995, 55:259-66.-   3. Kawamori, T. et al, Cancer Res., 1999, 59:597-601.-   4. Mahmood. N. N. et al, Carcinogenesis, 2000, 31:921-27.-   5. Subramanian, M. et al, Mutat. Res., 1994, 311:249-55.-   6. Tonnesen, H. H. et al, Int. J. Pharm., 1992, 87:79-87.-   7. Reddy, A. C. P. et al, Mol. Cell Biochem., 1994, 137:1-8.-   8. Donatus, I. A., Biochem. Pharmacol., 1990, 39:1869-75.-   9. Sharma. S. C. et al, Biochem. Pharmacol., 1972, 21:1210-14.-   10. Liu, J. V. et al, Carcinogenesis, 1993, 14:857-61.-   11. Huang, T. S. et al, Proc. Natl. Acad. Sci., 1991, 88:5292-96.-   12. Huang, M-T. et al, In L. W. Battenberg (ed.) Cancer Chemo    prevention, CRC Press, Boca Raton, 1992, pp 375-91.-   13. Huang. M. T. et al, Cancer Res., 1991, 51:813-19.-   14. Zhang, F. et al, Carcinogenesis, 1999, 20:445-51.-   15. Plummer, S. et al, Oncogene, 1999, 18:6013-20.-   16. Funk, C. D. et al, FASEB J., 1991, 5:2304-12.-   17. Subbaramiah, K. et al, 1996, Cancer Res., 1996, 56:4424-29.-   18. DuBois, R. N. et al. J. Clin. Invest., 1994, 93:493-98.-   19. Kelley, D. J. et al, Carcinogenesis, 1997, 18:795-99.-   20. Huang, M. T., et al Cancer Res., 1988, 48:5941-46; 1991,    51:813-19.-   21. Rao, C. V. et al., Cancer Res., 1995, 55:259-66.-   22. Ireson, C. R. et al, Cancer Res., 2001, 41:1058-64.-   23. Sharma, R. A. et al, Clin. Cancer Res., 2001, 7:1834-1900.-   24. Pan, M. H. et al, Drug Metabol. Dispos., 1999, 27:486-94.-   25. Asai, A., et al, Life Sci., 2000, 67:2785-93.-   26. Ireson et at, loc. cit.-   27. Ireson, C. R. et al, Cancer Epidemiol. Biomark. Prev., 2002,    11:105-11.-   28.3 Ravindranath, V. and Chandrasekhara, N., Toxicology, 1981,    20:251-57.-   29. Asai et al, loc cit.-   30. Ireson, C. R., et al, Cancer Epidemiol. Biomark. Prev., 2002,    11:105-11.-   31. Perkins, S. et al, Cancer Epidemiol. Biomark. Prev., 2002,    11:535-40.-   32. Limtrakul, P., et at, Cancer Lett., 1997, 116:197-203.-   33. Chiang, S. E. et al, Carcinogenesis, 2000, 21:331-35.-   34. Inano, H. et al, Carcinogenesis, 2000, 21:1835-41; Int. J.    Radiat. Oncol. Biol. Phys., 2002, 52:212-23; ibid, 2002, 53:735-43.-   35. Garcea, G. et al, Cancer Epidemiol. Biomark. Prev., 2005,    14:120-25.-   36. Shobha et al, Planta Med., 1998, 64:353-56

We claim:
 1. A method of treating a central nervous system disorder in asubject in need thereof, the method comprising administering to saidsubject in need thereof a composition comprising an effective amount ofa blend consisting of: a.) a curcuminoid mixture consisting of curcumin,demethoxycurcumin, and bisdemethoxycurcumin; and b.) a fraction ofessential oil of turmeric comprising 45% ar-turmerone, wherein theweight ratio of a.) to b.) in the blend is about 1:3 to about 99:1, andwherein the central nervous system disorder is depression.
 2. The methodof claim 1, wherein the weight ratio of a.) to b.) is about 10:1.
 3. Themethod of claim 1, wherein the weight ratio of a.) to b.) is about 12:1.4. The method of claim 1, wherein the effective amount of the blend isabout 500 mg.
 5. The method of claim 1, wherein a.) is in an amount ofabout 454.55 mg.
 6. The method of claim 1, wherein b.) is in an amountof about 45.45 mg.
 7. The method of claim 1, wherein a.) is in an amountof about 461.55 mg.
 8. The method of claim 1, wherein b.) is in anamount of about 38.5 mg.
 9. The method of claim 1, wherein a.) is in anamount of about 454.55 mg, and b.) is in an amount of about 45.45 mg.10. The method of claim 1, wherein a,) is in an amount of about 461.5mg, and b.) is in an amount of about 38.5 mg.
 11. The method of claim 1,wherein the composition is a gelatin capsule.
 12. The method of claim11, wherein the gelatin capsule comprises 500 mg of the blend.
 13. Themethod of claim 12, wherein the gelatin capsule is administered twicedaily for 8 weeks.
 14. The method of claim 1, wherein administering thecomposition improves the response rate of the subject on a HamiltonDepression rate scale after two months.
 15. The method of claim 14,wherein the response rate of the subject on the Hamilton Depression ratescale decreases from about 21 to about 7 two months after administeringthe composition.
 16. The method of claim 14, wherein the response rateof the subject on the Hamilton Depression rate scale improves by about65% after administering the composition.
 17. The method of claim 14,wherein the response rate of the subject on the Hamilton Depression ratescale improves by about 52% after administering the composition.
 18. Themethod of claim 1, wherein administering the composition improves theClinical Global Severity score (CGI-S) of the subject.
 19. The method ofclaim 18, wherein the Clinical Global Severity score (CGI-S) decreasesfrom about 5 to about
 1. 20. The method of claim 18, wherein theClinical Global Severity score (CGI-S) improves by about 75%.
 21. Themethod of claim 18, wherein the Clinical Global Severity score (CGI-S)improves by about 60%.
 22. The method of claim 18, wherein administeringthe composition improves the Global Change scale (CGI-I) score of thesubject.
 23. The method of claim 22, wherein the Global Change scale(CGI-I) score decreases from about 5 to about 2 after administering thecomposition to the subject.
 24. The method of claim 22, wherein theGlobal Change scale (CGI-I) score improves about 60% after administeringthe composition to the subject.
 25. The method of claim 22, wherein theGlobal Change scale (CGI-I) score improves about 50% after administeringthe composition to the subject.
 26. The method of claim 1, wherein theblend is prepared by the method comprising: suspending a.) in water toform a suspension; adding b.) to the suspension to form a mixture;homogenizing the mixture to obtain a slurry; and drying the slurry underheat and vacuum to form the blend.